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Abstract
Shortages of anesthesia medications pose significant risks to patient safety. Despite this,
no standardized educational program was located to regularly update practicing
anesthesia providers nor was this topic identified by the Council on Accreditation of
Nurse Anesthesia Educational Programs as a requirement for nurse anesthesia training
programs. The purpose of this project was to develop an evidence-based Teaching Plan
for novice certified registered nurse anesthetists. A directed content analysis identified
key themes from relevant literature. Themes included counts and patterns of medication
shortages, lack of alternatives, impact on patient safety, professional concerns related to
changes in practice, quality concerns, characteristics, causative factors of drugs
commonly in shortage, implications of shortages on anesthesia delivery, and suggested
interventions to mitigate the effects of drug shortages on anesthesia delivery and patient
safety outcomes. A draft Teaching Plan was developed from identified themes. Eighteen
content areas on the plan were submitted to a panel of 23 experts using an Expert Content
Validity Form with a 4-point scale. Twelve Expert Content Validity Forms were returned
with a response rate of 52%. The Item Content Validity Index range was 0.80 to 1.00 and
the Survey Content Validity Index was 0.88. Comments recorded by experts were
reviewed for possible inclusion, exclusion, or editing of content areas. Following review
of Item Content Validity Index scores and qualitative comments on the content areas of
the draft Teaching Plan, the draft content areas and Teaching Plan were accepted.

Keywords: medication shortage, novice certified registered nurse anesthetist, patient
safety, educational intervention
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An Evidence-Based Teaching Plan for Novice Certified Registered Nurse
Anesthetists on Medication Shortage Safety Threats and Management
A survey of patient safety officers, pharmacy leaders, and purchasing agents
conducted in 2012 and 2017 by the Institute for Safe Medication Practices (ISMP) found
that anesthesia delivery was the most prevalent or second most prevalent area of
medication shortages (Meyer, 2012, 2019). (See Figure 1). Respondents overwhelmingly
reported that shortages of medications posed increased risks to patients and compromised
delivery of care (Meyer, 2019). Many respondents (71%) indicated that, during shortages,
healthcare providers did not have the recommended medications available for specific
patient indications (Meyer, 2019). Fifty-five percent of respondents experienced
shortages exceeding 21 medications within the prior 6-month period (ISMP, 2018)
Results suggested that about half of respondents (47%) may believe that patients received
less efficacious medications during periods of medication shortage (Meyer, 2019). In
addition, 27% of respondents indicated they experienced shortages on a weekly basis,
whereas 66% of respondents encountered medication shortages daily (American Society
of Health-System Pharmacists [ASHP], 2017).
A drug shortage survey of 1,373 American Society of Anesthesiologists (ASA)
members revealed that 90% of surveyed providers had experienced at least one
medication shortage, while 98% of the respondents reported at least one shortage in the
past year (Meyer, 2012). In 2018, the ASA conducted an informal survey that noted 98%
of anesthesia providers experience frequent medication shortages and 95% believed
shortages play a role in how anesthesia is delivered to patients (ASA, 2018). These data
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points highlight the poor progress made in medication shortages between 2012 and 2018
and emphasize the ongoing problem anesthesia providers face in daily practice.
A variety of factors contribute to medication shortages: manufacturing and quality
control failures resulting in broken glass contaminating medication vials, bacterial
contamination of medications, declines in number of drug suppliers, low profit-margins
on generic medications resulting in low production and shortages, and dubious marketing
and business practices where pharmaceutical companies pay a rival generic company to
avoid or delay manufacturing a generic version of a newly off-patent drug (U.S.
Government Accountability Office [GAO], 2016). In addition, older medications used in
practice like glycopyrrolate, neostigmine, or ephedrine, may be off-patent or only have
one supplier due to regulatory factors (Fox & Tyler, 2017; Hamel & Recker, 2018).
Single source supply can lead to price hyperinflation. Glycopyrrolate, a single source
supplied medication, went into shortage and resulted in a price increase of 2,278% (Fox
& Tyler, 2017). Increased medication cost may promote alternative and less efficacious
medication use or increase health system costs (Fox & Tyler, 2017; Hamel & Recker,
2018). In addition to the risk of hyperinflation of single-source medications, hospitals
reported increased costs during times of shortage. These additional costs stem from the
labor required to manage drug shortages. A few examples of the increased labor include
revising electronic health records and protocols, dividing larger vials of medications into
syringes under sterile conditions, notifying providers of the shortage and adjustments to
protocols, and time spent acquiring additional drug from alternative suppliers (American
Association of Nurses Anesthetists [AANA], 2019; U.S. Food and Drug Administration
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[FDA], 2020a). Tucker et al. (2020) has estimated national labor costs attributable to drug
shortages amounts to $359 million annually.
The recent global health crisis caused by the coronavirus disease 2019 (COVID19) has highlighted the ongoing struggle with medication shortages. During the COVID19 outbreak, the U.S. Healthcare System experienced an overwhelming demand for
medical supplies, equipment, as well as pharmacological agents to meet the surging needs
of patients affected by the pandemic. For COVID-19 cases resulting in advanced
respiratory compromise, treatment often requires mechanical ventilation. To manage
patients on ventilators, sedatives, analgesics, and paralytics are required to optimize
patient ventilation (Legaspi, 2020). Hospitals across the nation experienced progressive
shortages of commonly used medications, including fentanyl, midazolam, diprivan,
ketamine, rocuronium, vecuronium, cisatracurium, and dexmedetomidine (Legaspi,
2020). These agents are essential in maintaining adequate levels of sedation and
optimizing patient ventilation by synchronizing breathing patterns with the ventilator. As
a result of shortages of these medications, The New York Times reported physicians and
healthcare providers are resorting to second-line, third, and fourth-line medications in
management of ventilator-dependent COVID-19 patients (Legaspi, 2020).
The AANA (2021) has identified 48 essential anesthesia medications in active
shortage. Examples of essential medications in shortage include antiemetics, vasoactive
resuscitation medications, neuromuscular blockade reversal agents, and various
medications to treat pain (AANA, 2021). Statistics on the increased demand for most
commonly used sedatives, analgesics, and paralytic agents, which soared since the
outbreak of the coronavirus pandemic January 1, 2020, indicated a 192% increase in
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sedative and anesthetic use, 73% surge of analgesic use, and 397% higher demand for
neuromuscular blockers (Legaspi, 2020).
Medication shortages are a considerable patient safety threat when analyzed in the
context of potential adverse patient outcomes due to unavailability of preferred, first-line
medications and a need to replace or omit a pharmaceutical agent (Tucker et al., 2020).
The AANA (2021) maintains a database of anesthesia specific medications currently in
shortage. A list of all medications in shortage is available through the FDA’s drug
shortage database. The FDA’s database categorizes each drug by specific therapeutic
categories such as anesthesia or analgesia/addiction that can be selected to highlight
information pertinent to a specialty area (FDA, 2020b). The following list represents the
anesthesia therapeutic category from the FDA’s (2020b) drug shortage database and the
supplied reason for the shortage:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Alfentanil Injection (Discontinuation)
Atracurium Besylate Injection, USP (Discontinuation)
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride and Epinephrine Injection, USP (Currently in
Shortage)
Bupivacaine Hydrochloride Injection, USP (Currently in Shortage)
Cisatracurium Besylate Injection (Currently in Shortage)
Dexmedetomidine Injection (Currently in Shortage)
Dexmedetomidine Injection (Discontinuation)
Etomidate (Amidate) Injection (Discontinuation)
Etomidate Injection (Currently in Shortage)
Ketamine Injection (Currently in Shortage)
Lidocaine HCl Topical Jelly (Discontinuation)
Lidocaine Hydrochloride (Xylocaine) Injection (Currently in Shortage)
Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Currently in
Shortage)
Methadone Hydrochloride Injection (Currently in Shortage)
Midazolam Injection, USP (Currently in Shortage)
Oxycodone Hydrochloride Tablets (Discontinuation)
Oxymorphone Hydrochloride (Discontinuation)
Promethazine Hydrochloride Injection, Solution (Discontinuation)
Promethazine Suppository (Discontinuation)
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•
•
•
•

Propofol Injectable Emulsion (Currently in Shortage)
Rocuronium Bromide Injection (Resolved)
Ropivacaine Hydrochloride Injection (Currently in Shortage)
Vecuronium Bromide for Injection (Currently in Shortage)

Despite these databases, there is an ongoing concern about lack of transparency in
manufacturing practices and manufacturer decisions to alter a drug’s supply chain
(Tucker et al., 2020).
The incidence of new drugs in shortages increased from the early 2000s through
2011. Seventy new drug shortages were identified in 2006 reaching a peak of 267 new
drug shortages in 2011 (ASHP, n.d.). Since 2011, there has been a decline in the number
of new drug shortages reaching 129 new drugs in shortage in 2020 (See Figure 2) (ASHP,
n.d.). Despite the decline in new drug shortages, the duration in which drugs remain in
shortage has increased (See Figure 3) (FDA, 2013, 2014, 2015, 2016, 2017, 2018, 2019,
2020b; GAO, 2016). Tucker et al. (2020) determined the average duration of a drug
shortage lasts about a year.
Lack of federal legislation on manufacturing of drugs in shortages leads to
fluctuations in the saturation of the pharmaceutical industry. Pharmaceutical companies
and corporations are not subjected to legal accountability to maintain inventory of
medications or regulate cost. The pharmaceutical industry functions primarily on the
premise of the free market and their operations are based on supply and demand, with
balancing the needs of the customers, the marketplace, and shareholders with
corresponding price adjustments (Greenberg et al., 2015). In the event of shortage,
suspension of production, or rising costs, anesthesia providers and other healthcare
providers are responsible for finding alternative treatments. However, comparable
replacement agents do not exist for all core anesthetic agents (Tucker et al., 2020). In
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these situations, anesthesia providers are expected to radically alter their practice which
may inadvertently affect patient safety (Greenberg et al., 2015).
Anesthesia providers may have limited knowledge of non-formulary or nonstandard anesthetic medications and adjuncts during periods of shortages. Also, the
limited availability of commonly used anesthetics could challenge the competency levels
of providers (Geisz-Everson et al., 2019). Different classes of paralytic and paralysis
reversal medications, analgesics, including opioids and non-steroidal anti-inflammatory
medications, anxiolytics, antiemetics, local anesthetics, and sedatives have different
properties with nuanced interactions that may be unfamiliar to anesthesia providers
(Geisz-Everson et al., 2019; Greenberg et al., 2015). In addition, pharmaceutical
formularies often vary from health system to health system. Healthcare providers may not
be aware of or consult available resources cataloging current medication shortages,
including the FDA and the AANA databases.
A contributing factor to compromised patient safety is lack of standardized
protocols of alternative therapies developed by hospital systems to guide anesthesia
providers during anesthetic medication shortages. Hospital medication procurement
teams in health systems serve as safety gatekeepers to ensure a uniform provision of
adequate and efficient medications that fosters safe patient care with maintenance of
quality standards (ASHP, 2017). A strategy aimed at dealing with medication shortages
discussed by Legaspi (2020) include development of multidisciplinary committees led by
anesthesia providers who would be responsible for creating algorithms or protocols
targeting specific medication shortages.
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The cornerstone of crisis management is identifying the underlying factors
contributing to the problem. The U.S. Government Accountability Office (2016), Fox and
Tyler (2017), Hamel and Recker (2018), and Legaspi (2020) have highlighted some
prominent economic, regulatory, social, political, and organizational factors leading to
shortages of medications in acute care settings including failures of manufacturing and
quality controls, contamination or exposure to environmental factors, declining number
of suppliers, etc. Drug shortages produce direct and indirect impacts on safe patient care
including suboptimal pain management, erroneous drug administration, medication
overdosing, and even cardiac arrest refractory to resuscitation (Geisz-Everson et al.,
2019; Phuong et al., 2019; Vail et al., 2017). Mitigation strategies employed by
healthcare professionals, including anesthesia providers and pharmacists, entail
development of algorithms and guidelines for utilizing alternative agents without
compromising efficacy and minimizing adverse patient effects (Moore et al, 2021; Neff
et al., 2018; Salajegheh et al., 2020). In addition to these provider-based approaches,
Tucker et al. (2020) has suggested drug shortage legislation may be necessary.
Problem Statement
Due to medication shortages, healthcare providers, including anesthesia providers,
must revise well-understood and established medication protocols and implement new
practices that are less familiar, potentially increasing the risk of patient harm stemming
from inexperience with their technique, variability in patient response, and interaction
with other medications (AANA, 2019). Not only do medication shortages pose serious
adverse outcomes for patients, but they also introduce increased complexity to anesthesia
practice (Tucker et al., 2020). The potential patient complications include less effective
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perioperative pain management, an increase in postoperative complications, persistent
postsurgical pain, and increased healthcare costs (Mariano, 2018). In addition, medication
shortages contribute greatly to medication errors (Hicks & Becker, 2006). The ISMP
(2018) reported a 21% prevalence of medication errors as a direct effect of medication
shortages. In most cases, errors are caused by administration of incorrect medication dose
or concentration. Deviation from standard care poses a serious risk to patient safety by
requiring anesthesia providers to replace standard medications with alternative agents.
Needs Assessment
The needs assessment for the undertaken project was supported by the
testimonials received from the educational administrators and anesthesia clinical
practitioners at the Einstein Healthcare Network (EHN) who reported medication
shortages to constitute an ongoing challenge in the operations of patient care delivery
from the preoperative through intra- and postoperative phases of care. EHN is willing to
produce a letter of support this project as well as offer assistance with resources required
for a successful completion of this doctoral undertaking.
Anesthesia medication shortages pose a serious risk to patient safety by requiring
provider substitution of less familiar medications. They carry the potential for more
adverse effects (AANA, 2019). Certified registered nurse anesthetists (CRNA) are taught
evidence-based medication practices during the didactic portion of their training.
Evidence-based practice often recommends specific medications that are best suited for
the clinical technique or scenario. However, when novice CRNAs enter clinical practice,
they may be required to utilize unfamiliar alternatives due to medication shortages. The
persistence of shortages raises concerns about the level of knowledge novice CRNAs
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have and the variability they see when moving from clinical education situations to postgraduate practice (Geisz-Everson et al., 2019). Presently, no requirement was identified
in the Council on Accreditation of Nurse Anesthesia Educational Programs (COA)
Standards for Accreditation curriculum for medication shortages to be included in the
didactic portion of nurse anesthesia programs (COA, 2021). As a result, it is unclear how
often the topic of medication shortages and their impact on anesthesia delivery are taught
across all nurse anesthesia programs. There is value in collaboration among educators,
academic institutions, and clinical sites to communicate and educate on shortages, their
impact, and alternatives for clinical practice (AANA, 2019).
Purpose Statement
The purpose of this Doctor of Nursing Practice project was to develop an
evidence-based Teaching Plan to structure an educational intervention for novice CRNAs
on the topic of prevalence of anesthesia medication shortages, causes of medication
shortages, implications for anesthesia delivery, adaptation of practice in times of
shortage, resources available to identify medications in shortage, and ways health
systems attempt to mitigate the effects of drug shortages on patient safety outcomes. The
project’s Teaching Plan, when delivered as an educational intervention, has the potential
to affect safe, quality anesthesia care as novice CRNAs will have an increase in
knowledge of medication shortages, how shortages impact patient care, how health
systems adapt to shortages, and ways in which health systems and anesthesia providers
seek to mitigate the effects of medication shortages. The project directors (PDs) further
recognize the potential for this evidence-based Teaching Plan as a foundation for an
educational intervention to be used in new hire orientation programs, continuing

10

education/professional development programs, and nurse anesthesia program curricula.
Following implementation of the education intervention, novice CRNAs may be better
informed to establish guidelines or decision-making algorithms to mitigate effects of
anesthesia medication shortages at their healthcare institution.
Project Question
The project question is: What are the elements of an evidence-based Teaching
Plan, including instruction of anesthesia medication shortage task management,
situational awareness, and clinical decision making?
Conceptual Definitions
CRNA – A registered nurse who has satisfactorily completed an accredited nurse
anesthesia training program and certifying examination (ASA, 2019).
Novice – Beginners that have no experience with the situation in which they are
placed. Novices are taught rules to guide action, but novices face the inability to
use discretionary judgement (Benner, 1982).
Medication shortage – A supply disruption that affects how the pharmacy
prepares or dispenses a medication that might influence patient care when
prescribers must use an alternative agent due to limited supply (ASHP,
2017). Any given time interval when the market experiences a negative gap
between the supply and demand for a medication (Phuong, 2019).
Educational intervention – An initiative to enhance the level of knowledge or
understanding of a topic in the form of educational materials and/or group-based
learning (Wensing, 2008). A future intervention can be delivered in an
educational intervention provided during an instructional session and structured
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by an evidence-based teaching plan and matching PowerPoint slides and multiplechoice test questions.
Teaching Plan – A blueprint to achieve the goal and the objectives that have been
developed (Bastable, 2019). A teaching plan should incorporate the following
elements: 1) purpose, 2) statement of the overall goal, 3) list of objectives, 4) an
outline of the content to be covered in the teaching session, 5) instructional
methods used for teaching the related content, 6) time allotted for the teaching of
each objective, 7) instructional resources needed, 8) method(s) used to evaluate
learning (Bastable, 2019).
Review of the Literature
Search Process Methods
The initial search process yielded 1,887 articles from 7 databases: La Salle
University’s Summon, CINAHL, Medline, ProQuest, PubMed, Joanna Briggs Institute,
and Cochrane Library. Keyword search terms used during the literature search included:
medication, shortages, anesth* with the Boolean operator “AND” in order to delineate
gathered material based on abstract, relevance, and inclusion criteria. Inclusion criteria
for research articles included studies published in the English language between 2016 and
2021, performed in the United States, peer reviewed, and full text. Following the search,
duplicate articles were omitted. CINAHL and PubMed yielded one article each after
initial title review, however, both articles were duplicates and are omitted from the search
process review matrix (See Table 1). Following the search process, 8 articles met
inclusion criteria. Articles were analyzed in matrix format (See Table 2). All articles were
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appraised utilizing the Johns Hopkins Nursing Evidence Level (I-V) and Quality (A-B-C)
Guide.
Appraised Studies
Neff et al. (2018) conducted a retrospective observational study to test the
incidence of patient postoperative nausea and vomiting (PONV) for periods before,
during, and after propofol shortage with evidence of increased incidence of PONV (11%
versus 5%) during the period of shortage of the anesthetic agent. The sample consisted of
2,090 patients who had undergone ambulatory surgery between August 2012 and April
2013 at a multispecialty, freestanding ambulatory surgery facility. Data were collected
using an electronic anesthesia database (Centricity, GE Healthcare). The researchers
obtained patients’ medical records from the post-anesthesia recovery phase as well as
post-operative follow-up documentation. Inclusion criteria specified individuals older
than 18 years who underwent general anesthesia. Exclusion criteria identified minors less
than 18 years of age. No conceptual framework was identified. Patients were divided into
three groups based on the timeframe of receiving anesthesia: group 1 before the propofol
shortages (August through October 2012), group 2 during the shortage (November 2012
through mid-January 2013) and group 3 after the shortages (late January through April
2013). A comparable sample sizes was utilized with group 1 including 662 participants;
group 2, 728; and group 3, 700. The researchers utilized SAS version 9.3 (SAS Institute)
to perform a statistical analysis.
The study revealed a statistically higher incidence of PONV in patients who have
undergone general anesthesia during the period of propofol shortage, as well as a greater
incidence of rescue antiemetic use and longer recovery phase in the post-anesthesia care
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unit (PACU) (Neff et al., 2018). Logistic regression showed that patients had a 2-fold
increase in the incidence of PONV during the propofol shortage when accounting for all
preexisting risk factors (nonsmoker, history of motion sickness, N/V from reading in a
vehicle, female gender, and history of PONV) (OR= 2.3; 95% CI= 1.5-3.5; p < 0.001).
Several limitations identified by the researchers, including limited generalizability of the
study results in other settings, data collection from retrospective computer documentation
that may have been biased by documentation inaccuracies or underreporting of PONV, as
well as a short duration of the propofol shortage that may have yielded an insufficient
sample size to produce significant findings. The researchers recommend adoption of
clearly determined PONV mitigation strategies (development of a risk-stratified
antiemetic protocol) in the peri-operative/postoperative period to patients undergoing
general anesthesia in the future when propofol agent might be in shortage.
Moore et al. (2021) implemented an evidence-based practice improvement
initiative which entailed introduction of Apfel Simplified Score to reduce the incidence of
PONV in high-risk surgical population during shortage of ondansetron at Naval Hospital
in Jacksonville, FL. This validated instrument was designed to identify patients at high
risk for developing PONV in the post-operative period and target preemptive
implementation of PONV mitigation strategies. Hour-long teaching sessions, including a
video-based demonstration, were conducted for the PACU nurses and anesthesia
providers on the proper use of the Apfel Score tool. Pre-assessment and post-assessment
evaluations were done to determine the level of knowledge prior to and following the
teaching intervention, as well as the extent of knowledge capture. Another measure
undertaken by the researchers to evaluate the efficacy of the training was a retrospective
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chart review of surgical patients who received anesthesia in the timeframe prior to the
teaching intervention. Rates of documented PONV were retrieved from post-operative
patient heath records. Inclusion criteria involved area of five highest-volume surgical
services (orthopedics, gynecology, general surgery, urology, and otolaryngology), patient
age between 18 and 89-years, and the ASA score between 1 and 3. Exclusion criteria
were determined by the emergent status of a surgery, pregnancy in patients, or presence
of nausea and/or vomiting during preoperative assessment. Baseline data from the period
prior to implementation of the teaching intervention, were collected from 150 patient
records (30 records per each service line). Additional data from 150 heath records were
collected approximately 8 months following project initiation. The Apfel scoring system
stratified patients at risk for developing PONV based on anticipated use of opioids in the
postoperative period, history of PONV and/or motion sickness, female gender, and
nonsmoker. Based on patient’s Apfel score, the recommendations were made for specific
antiemetic protocol adherence. No conceptual framework guided the study.
Statistical analysis was performed by using the Statistical Package for the Social
Sciences (SPSS) version 22.0 (Moore et al., 2021). The researchers measured the
outcomes of clinicians’ adherence to the Apfel score utilization and corresponding
antiemetic therapy prescription and, incidence of PONV. Significance of categorical data
and provider adherence were evaluated by chi-squared test. A statistically significant
increase in clinician adherence to the antiemetic protocol was determined in phase
following the teaching intervention (p = 0.002, OR = 2.31, 95% CI = 1.33-4.04). The
researchers noted an increase in the number of patients medicated appropriately (47% of
baseline cases versus 59% of final cases) for nausea indication based on Apfel scores (p =
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0.006). Ondansetron shortage during the early phase of project implementation impacted
the use of antiemetic agents and was reported as a limitation of the study; ondansetron is
the most prevalent and efficacious antiemetic agent prescribed in the postoperative
period. Given unavailability of ondansetron, other medications were recommended for
the indication of PONV, including haloperidol, promethazine, aprepitant, and
scopolamine which served as a guideline for nausea prophylaxis and treatment in
inadvertent periods of shortages in the future (Moore et al., 2021). Another limitation
entailed inability to capture patients who suffered from PONV within 24 hours from
receiving anesthesia as well as a considerably low sample size to accurately assess the
impact of preventing PONV in patients with the lowest and the highest Apfel scores. The
study’s outcome of increased practitioner adherence to utilizing Apfel scores and
corresponding algorithm for antiemetic administration and the resultant slightly reduced
rates of PONV were disseminated throughout the Military Health System, and the
practices are intended to be adopted by systemwide operation military medical personnel.
Salajegheh et al. (2020) conducted a segmented regression analysis of interrupted
time series to examine the efficacy of an oral opioid use versus intravenous (IV) narcotic
analgesic use and patient reported pain scores in the PACU area prior to and after
implementation of oral opioid protocol in times of parenteral opioid shortage. A
convenience sample of 29, 621 surgical cases performed between July 1, 2017 and May
31, 2019 (9 months pre-intervention and 14 months post-intervention) met inclusion
criteria for the study that included all surgical cases documented in the electronic health
record at the University of Virginia Health Center. Exclusion criteria specified patient
age less than 18 years-old, ASA score 5 and 6, patients who did not have a documented

16

pain score in PACU within 2 hours of competing the surgery, patients undergoing cardiac
surgery, and patients who remained intubated postoperatively. The researchers
formulated and implemented the Limited Intravenous Opioid Guideline by incorporating
multimodal nonopioid adjunct agents and oral opioids converted to equivalents of
milligrams of IV morphine (ME), which were comparable to manage postoperative pain
following its adaptation during IV opioid shortage. Patient self-reported pain scores on a
11-point numerical scale were recorded in PACU.
Descriptive statistics and regression models were performed in R version 3.3.2,
whereas the segmented regression analyses of interrupted time series were done in SPSS
version 24 (Salajegheh et al., 2020). The researchers noted a significant reduction in use
of total (p < 0.001) and parenteral (p < 0.001) opioids in the management of
postoperative pain following implementation of opioid-sparing guideline. Pain scores
reported in PACU by patients did not have significant differences prior to and after
adaptation of the protocol, although the alpha level was 0.69 (Estimate: 0.05, SE:0.13).
The researchers recommended adaptability of their parenteral opioid-sparing guideline,
framed by utilization of non-opioid adjuvant medications, enteral narcotic analgesic
agents, and local-regional anesthesia. Results showed a significant reduction in the
requirement of total, intravenous, and oral opioids during the recovery phase of
anesthesia following implementation of the guideline. They stated the feasibility of the
intervention for adaption in low- and middle-income countries with limited access to IV
opioids for management of postoperative pain. They acknowledged a study limitation of
not evaluating patient pain scores after discharge from the PACU. Therefore, they
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recommend further research to determine whether an opioid sparing pain management is
associated with reduced hospital and post-discharge opioid requirements.
O’Reilly-Shah and Lyde (2018) sought to evaluate the pharmacokinetics of
hydromorphone administered intrathecally to parturients. Increasing shortages of fentanyl
and sufentanil provided a framework for their inquiry. Prior literature questioned the
efficacy of intrathecal hydromorphone administration due to the length of time required
to provide adequate pain relief. The researchers’ objective was to reject their null
hypothesis that hydromorphone is an ineffective analgesic for laboring parturients. In
addition, they sought to establish the median time of onset. Convenience sampling from
January 2013 to June enrolled 20 Black or Hispanic parturients in the study. Criteria for
inclusion in the study included cervical dilation ≥ 3 cm and self-reported pain greater
than 5 out of 10 during contractions. Exclusion criteria included difficulty understanding
English, an ASA physical status classification ≥ 3, cervical dilation > 7 cm, category 2 or
3 fetal heart tones, known fetal anomaly, prior laparotomy, greater than two prior
Cesarean sections, contraindications to neuraxial anesthesia, allergy or hypersensitivity to
hydromorphone, severe liver or renal impairment, administration of opioids or sedating
agents during labor, or severe respiratory disease. Following evaluation of
inclusion/exclusion criteria and obtaining informed consent, a combined spinal-epidural
was placed an initial dose of 12 micrograms of hydromorphone was administered
intrathecally. The threshold for acceptable pain was established at a 3 out of 10. This
threshold was established because it is at the top end of “mild pain.” If the patient
experienced pain of less than a 3 out of 10 30 minutes following the initial
administration, the next dose was decreased by 2 micrograms. If the patient experienced
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pain greater than a 3 out of 10, the next dose was increased by 2 micrograms. Side effects
were monitored at one hour and one day post-delivery. Following administration, patients
were also monitored for clinical compromise such as hypotension, respiratory depression,
and fetal bradycardia for 12 hours post-injection. In addition to these potential side
effects, Apgar scores at 1 minute and 5 minutes were monitored. Utilizing Dixon and
Massey’s up-and-down methodology, the effective dose (ED50) was calculated based on
patient self-reported pain scores and dosing requirements (O’Reilly-Shah & Lyde, 2018).
In addition, timing to achieve effective pain management was also calculated for those
who achieved pain relief.
O’Reilly-Shah and Lyde (2018) found that the ED50 dose of intrathecal
hydromorphone was 10.9 mcg (CI = 5.6-16.2 mcg, p = .05). The duration to onset of pain
relief was 24 minutes. One baby had a 1-minute Apgar score of less than 7, however, all
babies had an Apgar score of ≥ 8. The results indicated that the effective dose was
consistent with prior research but the duration to onset of pain relief is too long. Most
parturients desired immediate or near-immediate pain relief and 24 minutes to onset of
pain relief is not clinically useful. Limitations of the study include low sample size,
limited racial diversity of the sample, no control of factors that may lead to increased pain
during labor such as shoulder dystocia, the ED50 is a singular data point and cannot be
extrapolated to establish and effective dose for 95% (ED95) or 99% (ED99) of the
population, and the study design did not allow for prolonged effects of hydromorphone
on labor analgesia. Further, sufentanil and fentanyl are established modalities for labor
analgesia. However, increasing shortages of narcotics and limited preservative-free
options present a dilemma to the laboring parturient who desires pain relief. As a result,
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the use of hydromorphone represented a potential alternative; however, the prolonged
duration of time to desired pain relief raises the question of its clinical utility as a sole
agent. In the event of a fentanyl and sufentanil shortage, O’Reilly-Shah and Lyde (2018)
suggested small doses of local anesthetic intrathecally in lieu of hydromorphone.
Blaine et al. (2016) compared epsilon-aminocaproic acid (εACA) with tranexamic
acid (TXA) during a national εACA shortage. εACA is a key medication used in blood
conservation during cardiac procedures at this research institution. In 2013, εACA went
into shortage due to required manufacturing upgrades by the Food and Drug
Administration (FDA). As a result, εACA stores at the institution were exhausted and
from April 1 2013 until June 4, 2013, TXA was substituted. The researchers compared
TXA and εACA and their impact on postoperative bleeding following cardiac surgery.
The retrospective cohort study period ran from February 1 through June 3, 2013 to
include usual care and comparison care cohorts. The usual care cohort of patients were
selected from the period of February 1 through March 31, 2013 and the comparison
cohort was selected April 1 through June 3, 2013. During this period, 158 patients
received cardiac surgery with cardiopulmonary bypass; 129 patients were selected for
inclusion. Exclusion criteria included repeat surgeries, non-cardiac lung transplantation
surgeries, intraoperative death, death within 8 hours of admission to the intensive care
unit, and surgical re-exploration within 8 hours. One patient who met inclusion criteria
was later excluded due to a history of hemophilia. Of those selected for inclusion, 68
received εACA and 60 received TXA. The primary endpoint of the study was
quantitative blood loss during the first 8 hours following surgery. Secondary endpoints
included the number of units of packed red blood cell, plasma, and platelets required
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during the first 8 hours postoperatively. Data about these endpoints was acquired from
patient charts.
Following review of charts, Blaine et al. (2016) found that their primary endpoint,
surgical drain output, did not differ statistically between the εACA and TXA cohorts.
Additionally, the secondary endpoints of transfusion requirements between εACA and
TXA found no statistical difference. However, patients receiving εACA required
additional rescue agents such as recombinant factor VII, factor VII inhibitor bypass
activity (FEIBA), and desmopressin. Blaine et al. (2016) acknowledged limitations in this
study that included the retrospective design, implementation of the study occurring at a
single institution, and exclusion of surgical estimated blood loss. Although not
acknowledged by the authors as a limitation, exclusion criteria eliminated patients who
required surgical exploration at 8 hours and death at 8 hours. Blaine et al. justified this
exclusion criteria by stating, “[A]ntifibrinolytic agents alone were unlikely to prevent
these complications” (Blaine et al., 2016, p. 517). While true, there is likely no single
causative factor to post-operative bleeding, an analysis of increased surgical reexploration or death between the two groups should have been considered. Blaine et al.
(2016) also noted an increase in rescue agent use with εACA when compared to TXA.
One may be able to question whether εACA resulted in increased post-operative bleeding
but was adequately managed by rescue agents before bleeding became statistically
significant. Blaine et al. (2016) suggested cost-effectiveness as an opportunity for future
work. Medication shortages can impose significant costs on healthcare institutions (Fox
& Tyler, 2017). Blaine et al. (2018) assessed the cost of TXA, εACA, rescue agents, and
blood products. The researchers noted that during their study period the research
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institution paid approximately $13.85 for εACA per cardiac case and $148 for TXA per
cardiac case. However, a single unit of packed red blood cells costs an estimated $761
and rescue agents can cost thousands of dollars per dose. As noted previously, the εACA
cohort required additional rescue agents. While there is no clear superior agent between
εACA and TXA, there may be additional cost related to rescue agents with the use of
εACA.
Wu et al. (2019) assessed whether remifentanil infusion for thyroid surgery was
associated with higher postoperative opioid use versus alternative intravenous opioid use
for intraoperative management in patients receiving thyroid surgery. Wu et al. (2018)
framed the study by noting that 5% of thyroid surgery patients may develop an opioid
addiction. In addition, remifentanil has been attributed to higher acute opioid tolerance
and postoperative hyperalgesia. Data were collected retrospectively from April 2016 until
July 2018. The remifentanil shortage occurred in December 2017 with supplies
diminishing towards February. A total of 497 patients receiving 500 total thyroidectomies
or thyroid lobectomies occurred during that period. The standard care period selected for
study occurred from April 1, 2016 through February 1, 2018. The shortage study period
occurred from February 2, 2018 through July 9, 2018. Only one patient was excluded
from the sample population. This exclusion was due to the patient receiving
intraoperative ketorolac and having secondary procedures performed at that the same
time. Of the 496 remaining participants, 83% received care outside of the shortage period
and 12% received care during the shortage period. To standardize equivalence of narcotic
between different agents, morphine milligram equivalents (MME) were used. Assessment
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of intraoperative opioid MME, postoperative MME requirements, and total MME were
the main points of study. Data were acquired by retrospective chart review.
During the standard care period, patients received on average 31 intraoperative
MME, 20 postoperative MME, and 54 total MME. During the shortage period, patients
received on average 39 intraoperative MME, 15 postoperative MME, and 58 total MME.
Postoperative MME during the shortage period was statistically significant (p = 0.05,
95% CI [0.39, 1.00]). In addition, as remifentanil dosage increased, there was an
increased likelihood that patients would require postoperative analgesia (p = 0.005, 95%
CI [1.08, 1.56]). Additional considerations made by Wu et al. (2019) were changes to
postoperative nausea and vomiting (p = 0.99) and discharge time (p = 0.7). None of these
outcomes were statistically significant. Limitations of this study included a limited period
in which patients remained under supervised care before discharge. This is important
because patients treated with remifentanil may have lingering hyperalgesia states once
discharged. Lingering hyperalgesia could result in increased opioid use postoperatively
compared to the study group. In addition, there was an appreciable difference between
types of surgeries performed during the two periods. During the standard care period,
there were a higher percentage of patients receiving total thyroidectomies versus the
study period which comprised a greater percentage of thyroid lobectomies. The study
highlights several implications for care. Remifentanil infusion is associated with
increased narcotic use postoperatively compared to the study period. The authors
theorized that the short-acting nature of remifentanil and potential hyperalgesia state
caused a required “catch up” period which the study group did not experience. The
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authors suggested more aggressive management of pain intraoperatively before
emergence and transport to the PACU.
Confronted with a national opioid shortage, Franz et al. (2019) conducted a
quality improvement (QI) project utilizing Plan-Do-Study-Act (PDSA) cycle to identify
alternative opioid-sparing analgesic regimens to prove to be efficacious and produce
comparable outcomes in the context of post-operative recovery time and reoperation
rates. The convenience sample consisted of 740 patients at Bellevue Surgery Center,
Washington and was divided into three groups: intraoperative morphine and
acetaminophen (M/A protocol)–333 patients, intraoperative dexmedetomidine and
preoperative ibuprofen (D/I protocol)–211 patients, and dexmedetomidine and ketorolac
(D/K protocol) with 196 patients. The inclusion criteria for the QI project included ASA
patients 1, 2, and 3 and, ages 2 to 19 years undergoing tonsillectomy and adenoidectomy
(T&A) between January 1, 2018 through March 1, 2019. The exclusion criteria consisted
of use of microdebrider technique, which historically showed lower pain scores, and
cases that did not adhere to intraoperative analgesic regimen. The D/K protocol effective
in managing postoperative pain following T&A surgery without increasing reoperation
rates and reduced rates of postoperative morphine administration from 100% to 20%. The
primary outcome measure was the pain score reported by patients in the recovery unit.
Scores were documented by the nursing staff based on Faces Pain Scale or FLACC pain
assessment method which was then converted to an 11-point (0-10) numerical pain scale.
Rates of rescue morphine analgesia administered in the PACU were considered the
second outcome measure. Data were extracted from patient’s electronic medical records
via a software tool MDmetrix OR advisor, visualized via statistical process control
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(SPC), and interpreted by utilization of Shewhart’s theory of variation. X-bar charts were
a form of organization for postoperative maximum pain scores and PACU length of stay
(LOS), whereas a P chart was used to present the weekly percentages of patients
undergoing T&A who required rescue morphine. No conceptual framework was
identified by the researchers to guide their study.
The X-bar chart depicting weekly PACU LOS indicated a 13-point increase of
mean (73.7 min) scores once the D/I protocol was instituted replacing M/A (Franz et al.,
2019). Given unfavorable outcome of the D/I algorithm, IV ketorolac was introduced in
the postoperative phase, which was analyzed in relation to morphine administration.
Weekly mean maximum pain scores proved to be comparable between M/A protocol
(3.9) and D/K (3.9). Comparison of weekly mean PACU LOS indicated lack of special
cause variations (SCV) with the D/K at 77.1 minutes versus 73.7 minutes in the M/A
cohort. Results evaluating morphine rescue rates were also insignificant between the D/K
group (19.6%) versus M/A protocol (25.6%). Project limitations were identified as
incompleteness of extracted data given lack of specific categories of data, which led to
inability to determine how many cases of T&As were excluded from the study. The
researchers also acknowledged lack of hemodynamic data describing each cohort.
Finally, the project outcomes may not be generalizable to all T&A patients, given a
variety of surgical techniques used and injection of local anesthetic (LA) by some
surgeons that might contribute to lower postoperative pain scores; however, these data
were not extracted from EMRs, so the association between use of LA and reduced postop pain levels may not be determined. The outcome of the quality improvement project
was formulation of an efficacious pain management protocol utilizing dexmedetomidine
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and ketorolac in times of IV opioid shortage which produced comparable pain relief
following T&A without extending recovery times or rates of reoperation within 30 days
postop. Additionally, the rate of perioperative IV morphine administration was
significantly reduced from 100 to 20%. No dissemination information or
recommendations for future research were included.
Tran et al. (2021) conducted a single-center retrospective cohort study at a 300bed, academic, tertiary care U.S. Veterans Affairs Medical Center between January 1,
208 and June 30, 2018 to evaluate the impact of intravenous opioid shortage on pain
scores of patients in the postoperative phase of care. The study sample consisted of 275
patients divided into two groups: 130 patients were evaluated before the time of shortage
(January 1, 2018 through March 28, 2018) and 145 patients in the post-shortage cohort
(March 29, 2018 through June 30, 2018). Inclusion criteria specified patients 18-years of
age and older, who had undergone a surgical procedure within specialty of general
surgery, orthopedics, cardiothoracic or vascular surgery, were admitted to the
postoperative acute care unit (PACU), and have required at least one dose of an IV opioid
analgesic in the postoperative phase of care. Patients were excluded if they were admitted
to the intensive care unit following the surgery, did not receive any IV narcotic within 7
days of the surgery, or if the dose of received narcotics could not have been precisely
established. Data were retrieved from patients’ electronic health records utilizing the
Veterans Informatics and Computing Infrastructure. Pain scores were assessed based on a
numerical rating scale from 0 to 10. Pain scores were documented by the PACU nursing
staff prior to opioid administration. IV opioids are indicated for management of moderate
and/or severe pain. Moderate pain is defined as 4 to 6, while severe pain is indicated as 7

26

to 10 based on a patient’s subjective pain reporting. Researchers did not refer to any
conceptual framework in the conception of their study.
Statistical analysis was performed utilizing chi-squared test to describe nominal
data, while nonparametric continuous data were analyzed via Mann-Whitney U test (Tran
et al., 2021). The total amount of doses of IV opioid analgesic used in the pre-shortage
cohort was found to be 442 (20.5%) versus 393 doses administered in the post-shortage
group (16.6%) (p < 0.01). Pain assessment revealed 38.4% moderate pain in the preshortage cohort compared to 42.1% in the post-shortage group (p = 0.01) and severe pain
scores were documented 58.5% in the pre-shortage period versus 55.6% in the postshortage time (p = 0.04). Researchers concluded a significant reduction in the number of
IV opioid doses administered in the cohort was affected by the shortage of parenteral
narcotics and increased number of severe pain scores when compared to the cohort in the
post-shortage time. A significant rise in the severity of pain reported by postoperative
patients was attributed to the limited accessibility of injectable opioids. No significant
differences were observed in the use of nonopioid analgesics or safety outcomes
associated with narcotics use, including respiratory depression, mortality, need for opioid
reversal, or hospital length of stay. Investigators acknowledged study limitations
including a selection bias given the observational nature of the study, not adjusting for
certain confounding factors including surgical techniques or preoperative pain
management, and availability of clinical pharmacists on the surgical teams guiding
analgesic prescribing protocols. The researchers recommended that the study’s results
become a guide for future studies pertaining to periods of shortage of injectable opioid
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agents and assist clinicians in developing protocols when encountering a limited
availability of opioids for postoperative pain management.
Related Literature
Hsia et al. (2015) noted there were few existing data points on whether patients
wanted to be informed about drug shortages prior to elective procedures. Deviations from
standard care raise ethical concerns. Hsia et al. (2015) was prompted by the shortage of
neostigmine which led to the use of edrophonium and atropine as the alternative agent.
The study question is, do patients want to be informed of deviation from standard care if
there are slight differences in side effects between the standard care and the alternative
care? Hsia et al. (2015) evaluated 949 Mayo Clinic patients that underwent elective
cholecystectomy during January 2011 to February 2014 at the Arizona and Florida Mayo
Clinic campuses for their desire to be informed if a medication shortage existed prior to
receiving care. Inclusion criteria consisted of having undergone elective laparoscopic
cholecystectomy and age greater than or equal to 18 years of age at the time of the
surgery. Of the 949 eligible patients, 502 were from the Florida campus and 447 from the
Arizona campus. Two hundred and fifty-eight patients responded to the survey reflecting
a response rate of 27.2%. The primary endpoint was percentage of participants who
preferred to be given the information on drug unavailability and therefore have the option
to postpone their elective surgery.
Results of the survey indicated that 76.2% (p < 0.0001, 95% CI = 70.5%- 81.3%)
of respondents wanted to know if there were “slight” differences between the standard
care and the alternative care (Hsia et al., 2015). Even if there were only “very slight”
differences, analogous to acetaminophen versus aspirin for a headache, 73.2% (p =
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0.0006) of respondents wanted to be informed. As the severity of the potential side effect
differences increased from very slight, to slight, to major differences, participants
willingness to proceed with surgery declined. With very slight differences, 39.6% (95%
CI = 31.1%-47.5%) wanted to proceed with elective surgery. With slight differences
36.7% (95% CI = 28.4%-44.6%) wanted to proceed with elective surgery. With major
differences 14.7% (95% CI = 9.2%-20.6%) wanted to proceed with elective surgery.
Limitations present in the study design included the method in which risk information
was presented to patients. Individuals have different learning and understanding styles
that may influence their risk assessment. Set and setting is also a key factor when a
patient may be assessing risk. This study assessed patients’ perceptions towards
differences in medications after they had the surgery. Results may vary if presented with
the information during the consent process preoperatively. Implications of this research
could inform anesthesia provider’s consent process to include a current medication
shortage. Healthcare has historically been paternalistic; however, this paradigm is shifting
towards patient-inclusivity. This research reflects patients may want knowledge about the
differences between the standard care drug and the alternative care during periods of
medication shortages impacting anesthesia delivery.
McLaughlin et al. (2013) assessed the effects of drug shortages on patient care.
Researchers sent an e-mail survey on October 2, 2012 to 1,516 directors of pharmacy.
Three subsequent e-mails were sent to encourage participation. Following the conclusion
of the survey on October 23, 2012, 193 responses were received reflecting a 13%
response rate. Most respondents were from acute care hospitals. Six categories were
assessed within the survey: demographics, adverse events, medication errors, patient
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outcomes, patient complaints, and institutional cost. Demographics included the type of
facility the respondent worked, location, number of patients served, and the drug category
of medication that were unavailable. Adverse events were based on the National Cancer
Institute Guidelines for Investigators: Adverse Event Reporting requirements. Total
adverse events resulting in death, permanent harm, and requiring intervention were listed.
Medication errors included the wrong drug dispensed or administered, the wrong dose
dispensed or administered, drug administered via the wrong route, drug given at the
incorrect frequency, drug given for the wrong indication, drug omission, and other.
Patient outcomes included delay of care or cancellations, death, treatment failure,
readmission due to treatment failure, increased length of hospitalization, increased patient
monitoring, patient transfer to another institution, delay of therapy, suboptimal treatment,
and use of alternative medications. Patient complaints were tallied: how many patients
complained about medication shortages and if patients were providing their own
medication due to shortage at the hospital. Finally, institutional cost was assessed based
on the number of full-time equivalencies (FTE) needed to manage medication shortages.
The most common category of medication unavailable was analgesics/anesthetics
(91.7%) (McLaughlin et al., 2013). Forty-two percent reported no possible or probable
adverse events stemming from drug shortages. However, 41.4% reported 1 to 5 possible
or probable adverse events and 3.4% greater than 15 possible or probable adverse events
stemming from drug shortages, 53% reported 1 to 10 medication errors, and 2.2%
reported greater than 30 medication errors. Serious medication errors were reported by
2.8% of respondents; 1.7% indicated 1 to 5 adverse events occurred that resulted in
permanent harm. Five percent of respondents indicated 1 to 5 adverse events occurred
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that required intervention to sustain life; 1.1% indicated that an adverse event likely
contributed to a patient death. The most common type of medication error was omission
at 55.5%; 21.4% of respondents noted greater than 10 delays of care for patients and
88.3% reported between 1 and 10 cancellations of care. Cancellations of care included
surgeries, procedures, and chemotherapy. Eighteen percent of respondents reported
greater than 10 patient complaints due to medication shortages with 9% of respondents
indicating patients had to supply their own medication during a shortage period. Seventythree percent estimated quarterly institutional costs associated with managing medication
shortages at greater than $100,000, with 26.6% of respondents indicating a required 0.6
to 1 FTE required to manage medication shortages. Limitations of the study include the
self-report nature of surveys. Individuals may not want to have disclosed potential
adverse events. Therefore, the results could be under-reported. In addition, the samples
were largely obtained from acute care institutions and may not reflect shortages at
different institutions. The researchers noted, however, that other survey results on the
topic share similar datapoints. This study provides insight into the frequency and severity
of adverse effects due to medication shortages. The data highlights that despite best
efforts and considerable cost, adverse events are readily attributable to shortages.
Substitution of a medication for one that is unavailable due to limited supply may
not be therapeutically equivalent and could pose a risk of increased adverse events. One
of the most significant patient safety concerns attributed to anesthetic agent shortages are
increased medication errors. Phuong et al. (2019) noted medication errors are directly
related to the practitioners’ lack of familiarity with the substituted agents. An instance
that highlights lack of familiarity resulting in a patient death comes from the AANA
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closed claims database. During a propofol shortage, methohexital was substituted as the
drug of choice for induction on a patient. The CRNA was unfamiliar with methohexital
and failed to dilute the medication appropriately. The patient received an overdose of
methohexital resulting in cardiac arrest on induction. The patient was successfully
resuscitated but suffered an anoxic brain injury and subsequently died a month later
(Geisz-Everson et al., 2019). Pharmacists have observed a lack of clinician knowledge as
it pertained to 54% of the alternative agents, specifically their mechanism of action,
adverse effects, or medication interactions (Phuong et al., 2019).
Use of alternative agents resulting in death is the most severe consequence of
medication shortages. Phuong et al.’s (2019) scoping review highlighted increased
mortality as a result of drug shortages in 10 of the 38 studies reviewed. Some studies
reported few deaths, whereas others could attribute hundreds of deaths to adverse effects
of medication shortages. One of the most pertinent examples to anesthesia practice
highlighted by Phuong et al. (2019) was a shortage of norepinephrine. Norepinephrine is
the first-line vasopressor for the treatment of septic shock. During a 5-year retrospective
cohort study of 27,835 patients with septic shock, alternative vasopressor use resulted in
a 3.7% increase in mortality (p = 0.03) (Phuong, et al., 2019; Vail et al., 2017).
Summary
There were few experimental and non-experimental studies found in the literature
review. Most study designs found during the literature review process were retrospective
cohort designs. This may be due to the accepted drug of choice for a given procedure
going into shortage. Researchers expressed a common theme of finding opportunity to
examine the differences on patient outcomes between standard care and alternative care
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during a drug shortage. Blaine et al. (2016), Moore et al. (2021), and Salajegheh et al.
(2020) showed little to no difference between the standard care and the alternative care.
O’Reilly-Shah et al. (2018) and Neff et al. (2018) showed negative outcomes with the
alternative agent. During a shortage, Franz et al. (2019), Tran et al. (2021), and Wu et al.
(2019) reported some measure of improvement with alternative drug use when compared
to the standard care.
The inconsistent findings highlight attempts to mitigate shortages and the inability
to circumvent some adverse outcomes despite best intentions. The PDs also acknowledge
that the available literature review is not exhaustive in discussing the researched concern
of shortages of anesthetic agents. The gap in literature serves as a recommendation for
future ongoing experimental studies to explore the ramifications of drug shortages on
patient safety, and formulation of evidence-based, reproducible, and universally adapted
guidelines for accommodation of anesthesia practice during times of drug shortage
without compromising efficacy and safety.
Theoretical Framework
The safety threat of shortages of anesthetic agents in the perioperative period is
conceptualized in the theoretical context of Human Error Theory (HET). HET was
developed by James Reason (2000) and finds its relevance in many spheres of systembased industries, including the technology, commercial airlines, and health care. The
premise of HET is founded on the inherent goal of a consumer-dependent market to attain
quality while not compromising safety. Common features of the mentioned industries
include safeguards, defenses, and barriers which aim at protecting customers from
potential hazards.
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Reason (2000) acknowledged that existing safety and defensive features also
experience faults in their design leading to inadvertent failure to keep consumers safe.
The author distinguished between two sets of factors contributing to errors, latent
conditions, and active failures. Latent conditions are considered inevitable decisions
made by the designers, writers, engineers, and conceptual creators that often stem from
error-conducive workplace environments, including deadlines, understaffing, lack of
adequate equipment, staff fatigue, or lack of experience (Reason, 2000). The second
factor, active failures, Reason states are related to human error committed while in direct
contact with the patient or system. Reason refers specifically to professionals such as
surgeons, anesthesia providers, pilots, or control room operators.
Medication safety threats in the perioperative period can be analyzed in the
context of both active failures as well as latent conditions, as conceptualized by Reason
(2000). The necessity to replace anesthetic agents with agents which are not routinely
utilized by the provider may lead to considerable errors in dosing administration,
accuracy of preparation, as well as potential for adverse effects including efficacy and
efficiency of action. Latent conditions are a significant factor in the context of medication
shortages. Examples include the anesthesia provider’s level of adaptability, critical
thinking, comprehensive knowledge of human physiology and pharmacokinetics, and
experience and familiarity with alternative agents and their side effect profiles. According
to Reason (2000), this kind of error is considered easier to identify and manage with
proactive management strategies facilitating adverse outcome prevention.
Active failures are more challenging to identify in a timely manner. The active
failures of Reason’s (2000) HET can be applied to the safety threat of anesthesia
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medication shortages as it pertains to “unsafe acts” committed by anesthesia providers
while in direct contact with the patient. The art and science of anesthesia combines an
extensive assortment of knowledge and skills which can differentiate between life or
death. The errors, as defined by Reason (2000), include human slips, lapses, fumbles,
mistakes, and procedural violations. The anesthesia providers are at risk of mismanaging
the patient without access to preferred and recommended agents for specific indication
The array of errors may include administering the wrong medication, incorrect dose,
incorrect concentration, underdosing, overdosing, and causing synergistic or inhibitory
effects contributing to adverse effects or poor tolerance by patients.
Method
Design
The evidence-based Teaching Plan was designed as a quality improvement project
to provide the foundation for an educational intervention for novice CRNAs. The
educational intervention, structured by an evidence-based Teaching Plan, can be
presented during an instructional session using matching PowerPoint slides and multiplechoice test questions. A directed content analysis (Table 3) in the context of HET was
used to provide evidence in support of major themes and patterns identified in the
reviewed literature (Hsieh & Shannon, 2005; Reason, 2000). The qualitative results from
the content analysis formed the basis of the Teaching Plan’s content. Each PD
individually assessed the reviewed literature for major themes identified and together
develop consensus of the overall identified themes and patterns.
An expert panel comprised of nurse anesthetists, hospital-based pharmacists, and
medication experts evaluated the draft Teaching Plan (Appendix A) to establish expert
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content validity of the content column of the draft Teaching Plan. The themes identified
through the content analysis process were translated into content for the Teaching Plan
that matches the Teaching Plans cognitive objectives. The draft Teaching Plan was
relevant to anesthesia practice as judged by expert reviewers. Appendix B includes the
expert content analysis instrument. This project culminated in the validation of the
Teaching Plan for novice CRNAs. A PowerPoint lecture and multiple-choice test items
can be developed based on the validated Teaching Plan by future PDs. The blueprint for
the draft Teaching Plan is included in Appendix A.
Sample and Setting
The sample for this project consists of two distinct data sources. The first sample
of the proposed project is the scholarly literature appraised for the content analysis.
Prominent codes and recurrent themes identified pertained to the impact of medication
shortages on delivery of anesthesia care, which became the foundation for the evidencebased content in the construction of the Teaching Plan. The second data source is the
conducted expert review panel who were tasked with determining content validity of the
proposed Teaching Plan content areas. The 12-person expert panel included nurse
anesthetists, hospital-based pharmacists, and traditional experts in the field of medication
shortages.
Ethical Considerations
Following completion of the project proposal defense, the project was submitted
to EHN’s Institutional Review Board (IRB) for review and was granted exempt status
due to anonymous data sources (i.e., published literature and expert reviewers) and no
involvement of human subjects as outlined in HRP-319 (Einstein Healthcare Network
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Investigator Manual, 2014). A copy of the IRB letter noting human subject research
exemption is provided in Appendix C. During the IRB process, the PDs have also
addressed additional HIPAA regulations by providing answers to the following required
items:
•
•
•
•
•
•
•

The activity description
The plan for data use
The plan for data protection (limited access, when and how data is stored,
password protection, etc.)
Any materials submitted within this determination and that will be used to
carry out the planned activity
Any data collection and master/linking sheets
Any surveys/questionnaires
Description of recruitment activities including invitations

Answers were submitted to EHN’s IRB for review. La Salle University accepted the
assessment of this project by EHN’s IRB and has provided a letter indicating no
additional IRB approval is required (Appendix D). Data collected from content experts
were stored with anonymized codes reflecting expert reviewers’ area of expertise (e.g.,
medication expert, pharmacist, nurse anesthetist).
Instrumentation
The project’s instruments included the content analysis matrix (Table 3) and the
Expert Content Validity Form developed for expert reviewers’ ratings of Teaching Plan
content (Appendix B). The PDs used the content analysis matrix (Table 3) to analyze
relevant literature. The PDs completed and an Expert Content Validity Form (Appendix
B) for topic experts to review the draft qualitative analysis of the literature as seen in
Table 3.
The Expert Content Validity Form (Appendix B) was created for topic experts to
review the 18 content areas of the draft Teaching Plan (Appendix A). The PDs requested
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content experts judge the relevancy of the content areas in the draft Teaching Plan.
Numerical data were analyzed using Microsoft Excel for ranks (1 = not relevant; 2 =
somewhat relevant; 3 = quite relevant; 4 = highly relevant). Judges’ comments on the 18
content areas were also copied into Microsoft Excel. Item content validity indexes (ICVIs) and a survey content validity index average (S-CVI/Ave) were calculated and
reviewed to consider changes to the draft Teaching Plan. Themes analyzed on experts’
comments were also reviewed (Polit & Beck, 2017).
Procedures for Data Collection
Data collection for the content analysis was based on the review of relevant
literature published during the past five years (2016-2021) on the topics of medication
shortages and anesthesia. During the directed content analysis, as described by Hsieh and
Shannon (2005), PDs referred to previous findings from the literature review to isolate
common themes which preceded data analysis. The project stemmed from a theoretical
foundation. The themes and codes were derived from the underpinning theoretical
framework or pertinent research findings (Hsieh & Shannon, 2005). Categories are
emerging patterns or themes identified in the text via a scrutinized analysis. The primary
benefit of a directed approach to content analysis was the ability to validate and amplify
existing theory.
The directed content analysis approach justified the scope of the intended
Teaching Plan. The draft Teaching Plan was also guided by concepts in the theoretical
framework. Following project proposal approval, both PDs conducted an independent
search of literature to identify recurring themes and codes as they pertain to the topic of
anesthetic medication shortages.
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The 18 content areas of the Draft Teaching plan (Appendix A) and the Expert
Content Validity Form (Appendix B) were submitted to a panel of 23 experts via email.
A letter of instruction was included with the expected 2-week timeline for completion.
After receiving completed Expert Content Validity Forms, ranks on the 4-point scale
were entered into Microsoft Excel for the 18 content areas of the Teaching Plan.
Additionally, qualitative comments were copied verbatim into the Microsoft Excel
Spreadsheet in corresponding cells that matched content areas.
Data Analysis
Content Analysis
Following review of the literature review, the PDs independently discerned
recurring themes and codes. Consensus was reached on the content analysis themes and
codes (Table 3) that served as the foundation for structuring the Teaching Plan content
columns. During the first draft of the content analysis, direct quotes were retrieved from
the relevant scholarly literature. The PDs agreed on their applicability to the Teaching
Plan. The PDs then summarized the direct quotes into generalizable statements with
broader applicability to relevant research. The finalized content analysis was reviewed by
the Project Team’s Chair and Reader and received approval. The content analysis
informed the proposed, translated material, in the development of the draft Teaching
Plan.
The overarching goal of the PDs undertaking this project was to increase novice
CRNAs’ knowledge pertaining to the prevalence of medication shortages in anesthesia
delivery. The completed content analysis shaped the content areas in a column of the
draft Teaching Plan and determined sub-concepts outlined within the Teaching Plan.
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Teaching Plan Development
Following the development of the content analysis, the themes and codes
discovered in the literature informed the content areas of the Teaching Plan. Draft
learning objectives were prepared based upon relevant literature analyzed. Estimated
timeframes for instruction of each content were outlined in the Teaching Plan. The
expected format and media of the Teaching Plan intervention to be implemented in the
future will be face-to-face instruction via a PowerPoint presentation. Prior to
disseminating the draft Teaching Plan to the panel of experts, the content column
concepts of the Teaching Plan were evaluated and validated by the Project Chair and the
Project Reader.
Expert Review Data Analysis
Quantitative and qualitative data from the expert content reviewers were analyzed
in Microsoft Excel. Content areas ranked 3 or 4 were interpreted as relevant to the
Teaching Plan and content areas ranked 1 or 2 were interpreted as not relevant or missing
a critical component (Polit & Beck, 2017). For each content area, the number of experts
ranking that area 3 or 4 were divided by the total number of experts to derive an I-CVI
(Polit & Beck, 2017). The PDs required individual content areas to achieve an I-CVI of
0.80 or greater to be accepted (Polit & Beck, 2017). The S-CVI/Ave was calculated by
summing the content area I-CVIs and dividing by the total number of content areas.
Experts’ comments were reviewed using thematic analysis for possible changes in
the content areas on concepts and sub-concepts, phrasing, and other pertinent insights.
Results
Content Analysis
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The results of the PDs’ analysis of the medication shortage literature (Table 3)
provided the basis for the content areas in the draft Teaching Plan. The results of this
translation process are found in Appendix A, content column. Appendix A represents the
draft and final Teaching Plan.
Out of 23 Expert Content Validity Forms, 12 were returned to the PDs, reflecting
a 52% response rate. Of the 12 experts, one was a traditional expert and the remaining 11
were clinical experts. All returned Expert Content Validity Forms were anonymous and
did not include personally identifiable information (Figure 4).
The range of I-CVIs was 0.80 to 1.00. Content areas 5, Quality Concerns for
Manufacturers and Providers of Medications, and 10, Economic Factors for
Manufacturers and Health Care Systems Centers, were the lowest I-CVIs at 0.80. Content
areas 16, Pharmacy Based Interventions, 17, Quality Improvement Hospitals, and 18,
Best Practices Anesthesia Providers Drug Shortages, had the highest I-CVIs at 1.00. The
S-CVI/Ave was 0.88. Results can be found in Table 4.
In reviewing the qualitative comments, close attention was paid to content areas 5
and 10 due to validity falling just above the validity threshold. Content area 5, Quality
Concerns for Manufacturers and Providers of Medications, was perceived by experts as
not relevant to bedside providers as CRNAs are unable to influence supply chain issues.
However, despite this commentary, other experts expressed content area 5 was an
important content area for novice CRNAs to know about in order to anticipate and
manage critical shortages. Content area 10, Economic Factors for Manufacturers and
Health Care Systems, was perceived by experts as not pertinent to the information
relayed to a novice CRNA but may be relevant to pharmacy medication purchasing

41

agents. The summary of constructive qualitative comments from the panel of experts is
outlined in Table 5.
Revised Teaching Plan
Based on validity, all I-CVIs were accepted and no content areas were modified.
Polit and Beck (2017) acknowledged no requirement for content revisions with I-CVIs
surpassing the threshold of 0.80. The PDs noticed two themes in the received comments:
1. Experts identified content areas that were not explicitly outlined in the
Teaching Plan that have been elucidated in the detailed content analysis. The PDs
recommend inclusion of these content areas in the future educational intervention.
2. Clinical experts may not be familiar with the most recent relevant research on
the topic. The PDs contend this helps validate the needs assessment and proposed
content areas for future educational intervention.
Based on these two themes, draft content areas remained unrevised in the final Teaching
Plan (Appendix A). In response to theme 1, the PDs recommend inclusion of the content
areas outlined in the content analysis in the future educational intervention. In response to
theme 2, the PDs contend that the disparity between anesthesia knowledge and scholarly
literature helps validate content areas and supports the needs assessment of providing
education to novice CRNAs. Additionally, the PDs also acknowledged the feedback from
the traditional expert on content area 2, Anesthesia Drug Shortages: Safety Threats. The
expert verified the significance of the topic as a foundation for complex understanding of
medication shortages; however, the expert suggested inclusion of more detailed, specific
examples of errors as a result of medication shortages such as omissions, dilution errors,
erroneous medication substitutions, etc., to enhance the illustration of the problem to the
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novice CRNA and substantiate the formulation of appropriate interventions. Access to
these real-world examples is limited by access to the AANA/ASA closed claims
databases. To improve assimilation of information by the novice CRNA, the traditional
expert suggested incorporation of alternative methods of instruction such as case studies.
The PDs acknowledge the value of this method of teaching and will include that
recommendation in the implications for future phase of the project implementation.
Following validation, the PDs accepted the draft Teaching Plan without revision.
The draft Teaching Plan is also the final Teaching Plan (See Appendix A).
Discussion
Drug shortages continue to be a pervasive threat to patient safety and patient
outcomes. Content validity based on literature and expert judgments defined the 18
content areas of the Teaching Plan. The teaching plan could structure an educational
intervention that bridges the gap between medication shortages and novice CRNA
knowledge about causative factors, resources available to identify medication shortages,
and mitigation strategies.
Content analysis of relevant literature generated recurrent themes originating in
direct quotes or paraphrased quotes extracted from the literature. The paraphrased quotes
were rephrased to represent a credible view and were agreed upon by both PDs. The draft
Teaching Plan’s content column was translated based on the content analysis. The DNP
Project Chair and Project Reader for the teaching plan evaluated the content analysis for
content development. Following their review, relevant changes were made to the
Teaching Plan.
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Initially, the content analysis themes were included on the Expert Content
Validity Form for expert reviewers to assess. A total of 23 experts received the Expert
Content Validity Form for review and validation of the Teaching Plan. Twelve forms
were received. The I-CVIs were highly relevant with an I-CVI range of 0.80 to 1.00 and a
S-CVI/Ave of 0.88.
The final version of the evidence-based Teaching Plan reflects current literature
on medication shortages and medication shortages relevant to anesthesia delivery. Few
studies were located in the literature review assessing the direct impact anesthesia
medication shortages have on patient outcomes. The Teaching Plan provides a validated
blueprint for an educational intervention. Elements of the Teaching Plan include a
purpose, statement of overall goal, list of cognitive objectives, content areas (translated
from literature into concepts and sub-concepts) for the Teaching Plan’s content column
and outlining the content to be covered in a future teaching session, instruction methods
for teaching the content, time allotted for teaching each objective, instructional resources,
and a multiple-choice test to evaluate learning (Bastable, 2019).
Access to AANA and ASA closed claims database may be beneficial for future
identification of morbidity and mortality outcomes related to anesthesia drug shortages.
Additionally, survey design studies were common in the reviewed literature. Most
assessed studies were retrospective study designs and reflective of a drug shortage
occurring and anesthesia providers assessing the impact of a necessary alternative agent.
Of the studies evaluated, a few included a mitigation strategy where a known adverse
side effect was likely to occur with the second-line agent.
Summary of Major Findings
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This project identified a need for continued research on the impact of medication
shortages on delivery of anesthesia. A significant gap exists between the limited
evidence-based literature discussing anesthetic shortages and studies addressing novice
CRNAs’ knowledge and clinical application adaptations in times of medication
shortages. The goal of this project has been met, which was to create an evidence-based
Teaching Plan for novice CRNAs to increase their situational awareness and task
management of anesthetic agents’ shortages and increase knowledge and clinical
decision-making capacity. The PDs have succeeded in establishing content validity of the
Teaching Plan by analysis of literature and judgments of a panel of experts in the field of
clinical anesthesia, medication shortages, and hospital-based pharmacy.
The 18 content areas of the Teaching Plan included content areas of safety threats
posed by anesthesia medication shortages in the context of limited alternative agents,
patient safety, professional concerns, and quality concerns for medication manufacturers,
prevalence and consequences of sterile injectable drug shortages, regulatory and
economic factors contributing to shortages of anesthetic mediations, concerns of national
disasters, national security and ethical considerations, mitigation strategies targeting
healthcare policies and procedures, pharmacy-based interventions and anesthesia
provider driven initiatives. All content areas included in the Teaching Plan were validated
quantitatively by ranks selected by the 12 members of the expert panel. However,
comments provided by the traditional expert were distinct from the clinical experts and
were more reflective of the reviewed literature (See Table 5). The comments might
represent a difference in the level of knowledge between various professionals depending
on their roles and level of exposure to the most relevant research.
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In the context of HET, the developed content areas generally described latent
conditions that could contribute to active failures. The content areas described the
multifactorial causative factors of medication shortages such as limited alternatives,
quality control concerns, single-source supply, and foreign reliance for drug supply.
These causative factors contribute to shortages and the deviation from standard care.
Unfamiliarity with alternative agents, no curricular requirement by the COA to educate
about medication shortages, and deviation from standard care, can predispose providers
to active failures. Of note, Geisz-Everson et al. (2019) noted similar themes in their
assessment of the AANA closed claims database. Of the five themes Geisz-Everson et al.
(2019) identified, three are similarly identified here: normalization of deviance,
knowledge deficit, and medication errors. The outcome of these latent conditions and
active failures identified include worse perioperative pain, underdosing or overdosing,
adverse patient outcomes, and unexpected synergistic or inhibitory effects.
Limitations
A limitation to the project is that the needs assessment requiring the development
of the Teaching Plan was performed in a single health care educational institution. The
literature review utilized as a data source for construction of the Teaching Plan was
limited with few studies demonstrating the impact of medication shortages on delivery of
anesthesia care. Inconsistent findings were identified in the reviewed literature pertaining
to the efficacy of mitigation strategies implemented by various healthcare institutions.
Lack of standardized algorithms for alternative anesthetic agent use in times of shortages
has also been documented. Also, this was the first time the PDs conducted qualitative
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analysis. Lastly, there was lack of diversity in the expert panel’s composition, with one
expert considered a traditional expert versus 11 clinical experts.
Implications
The overarching goal of this quality improvement project is to attain project
sustainability. The formulated Teaching Plan is to serve as a guideline for a future DNP
student registered nurse anesthetist (SRNA) cohort to implement an educational
intervention to novice CRNAs in a healthcare setting. The PDs recommend future
implementation of the educational intervention to include case studies, vignettes, and
problem-based learning to highlight situations in which medication shortages have led to
medication errors or patient harm. The educational intervention could be structured as a
pre-test post-test in order to assess improvements to level of knowledge. As the
instructional session is planned in the future, SRNAs might consider dividing the content
into separate sessions. Project implementation, sustainability, and dissemination may
include interdepartmental safety and quality initiatives for the anesthesia providers,
incorporation of educational intervention into novice CRNA orientation at a healthcare
institution, presented as annual training or anesthesia department annual presentation, or
future publication in a scholarly journal.
Areas for future research include assessing AANA and ASA closed claims
database for relevant data on adverse effects or medication errors caused by medication
shortages. Topics for studies or quality improvement initiatives on alternative agents and
their effects on patient outcomes may also provide suggestions for improvement as
isolated shortages occur in healthcare institutions.
Conclusion

47

Medication shortages were examined in the context of anesthesia delivery among
CRNAs because anesthetic shortages are a frequent occurrence and can significantly
impact safety of anesthesia delivery in a healthcare setting. Following completion of a
needs assessment at an academic medical center, literature review was performed to
substantiate the background and scope of the problem. Lack of a curricular requirement
by the COA prompted formulation of an evidence-based Teaching Plan. The goal was to
develop a quality improvement initiative to educate novice CRNAs on fundamental
information on anesthetic shortages, including patient safety implications, mitigation
strategies, and resources available. The significance of the project is determined by the
project’s goal to improve safety of anesthesia delivery in time of medication shortages.
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Table 1
Search Process Review of Literature
n
Database

Total Articles

Articles Remaining
After Title Review

Articles Retrieved
and Examined

Articles that fit
Inclusion Criteria

7

Articles Remaining
After Abstract
Review
6

La Salle University’s
Summon

921

6

6

Cochrane Library

25

0

0

0

0

Joanna Briggs
Institute EBP
Database
CINAHL

33

0

0

0

0

4

0

0

0

0

Medline

7

2

2

2

2

PubMed

140

0

0

0

0

1

0

0

0

ProQuest
757
Dissertations &
Theses Global
Note. Number of duplicate articles removed = 2
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Table 2
Review of Literature Matrix Systematized Review
Database
Purpose of
Theory or
# Article
Study
Conceptual
Framework
First
Major
Author,
Variables (IV,
Year
DV) or
(Full
Phenomenon
citation in
References)

Medline #1
Blaine,
2016

To compare the
effectiveness of
εACA versus
TXA in cardiac
surgery during
a εACA
shortage. IV –
Antifibrinolytic
(εACA or
TXA)
DV – Surgical
drainage and
number of
blood product
transfusions

None

Design

SingleCenter
Retrospective
cohort study

Measurement Data Analysis
Major
(Name of
Variables
Statistics,
(Instrument)
descriptive,
Inferential
and Results)

Milliliters of
surgical drain
output; Units
of packed red
blood cells;
Units of fresh
frozen
plasma;
number of 6pack of
platelets
transfused.
Data accessed
during
retrospective
chart analysis.
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Multivariate
linear
regression
with identified
confounders
adjusted by
stepwise
subtraction.
Statistical
analysis
performed
with R
Statistical
Software
(version
3.2.1). Power
analysis

Findings

A total of 128
patients met criteria.
60 received TXA and
68 received εACA.
Eight-hour surgical
drain output did not
differ between TXA
and εACA OR =
1.10 (95% CI = 0.97
– 1.26, p = 0.460).
Eight-hour
transfusion
requirements showed
no difference
between TXA and

Evidence
Level of
Research
&
Quality
Johns
Hopkins
Nursing
EvidenceBased
Practice
III-A

performed
using PASS
Statistical
Software.

Medline #2
Salajegheh,
2020

To introduce a
standardized
perioperative
opioid sparing
analgesic
guideline in
times of IV
opioid shortage
producing
comparable
pain control in
the PACU

None

A single
center
interrupted
time series
with
segmented
regression
analysis

All PACU
patientreported pain
score (11point
numerical
score)
recorded by
the nursing
staff were
averaged per
case. Mean
and median
pain scores for
each calendar
month from
July, 2017 to
May 2019
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Descriptive
statistics were
used to
describe
continuous
variables. Chisquare tests
were used to
compare
categorical
variables
(gender, ASA)
and linear
regression
models were
used to
compare
continuous
variables.

εACA OR = 1.79
(95% CI = 0.79 –
2.73, p = 0.176).
However, patients
receiving εACA
were more likely to
receive a rescue
hemostatic agent
when compared to
patients receiving
TXA (p = 0.039).
There was a
significant decrease
in total (Estimate: 39.9 mg, SE: 6.9 mg,
p < 0.001) and
parenteral opioid use
(Estimate: -51.6 mg,
SE: 7.1 mg, p <
0.001) after the
implementation of
the guideline with a
significant increase
in oral opioid use
(Estimate: 9.4 mg,
SE: 1.1 mg, p <
0.001). A sustained
decrease in total
(Estimate: -0.79 mg,
SE: 0.48 mg, p =

III-A

were
calculated.

Summon #1
Franz, 2019

To develop and
implement an
anesthetic
protocol for
pediatric
patients
undergoing
tonsillectomy
and
adenoidectomy
(T&A) which
would offer
adequate pain
management in
times of IV
opioid

None

A quality
improvement
project

Descriptive
statistics and
regression
models were
performed in
R Statistical
Software
(version
3.3.2). The
segmented
time-series
regression
analyses were
performed in
SPSS©.
Pain scores
Data for each
were recorded cohort were
by PACU
extracted
nurses using
using
either the
MDmetrix OR
Faces, Legs,
Advisor –
Activity, Cry, software tool
Consolability that allows
tool (FLACC; querying of
validity r =
health
0.41-0.8,
information
reliability
from
61%-91%, κ = perioperative
0.52-0.82),
data sourced
Faces Pain
from the
Scale-Revised hospitals
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0.11), oral (Estimate:
-0.41 mg, SE: 0.11
mg, p = 0.001) and
parenteral (Estimate:
-0.24 mg, SE: 0.49
mg, p = 0.64) opioid
use was noted
following the
intervention.

The percentage of
T&A patients
receiving
perioperative
morphine dropped
from 100% to 20%.
Fewer patients in the
D/K group (77, 39%)
received
postoperative oral
acetaminophen than
the D/I group (101,
48%). Four D/K
patients (2%)
received oxycodone.
Likewise, for the

V-B

shortage. DV –
Maximum pain
score in the
PACU and
postoperative
morphine
rescue rates in
PACU

Summon #2
Moore,
2021

To reduce the
incidence of
PONV by
proper use of
Apfel scoring
system in time
of ondansetron
shortage

None

An evidencebased
practice
improvement
initiative

(FPS-R;
validity r =
0.84-0.99,
inter-rater
correlation r =
0.84-0.99), or
a numerical 010 Visual
Analog Scale
(VAS;
validity r =
0.61-0.90,
reliability r =
0.41-0.58,
inter-rater
correlation r =
0.28-0.72).
Each of these
was converted
to an 11-point
(0-10) scoring
system for
analysis.
Rates of
PONV were
extracted from
PACU
nursing
records
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electronic
balancing measure of
medical record weekly mean PACU
(EMR).
LOS, no SCV was
seen with the D/K
protocol (77.1
minutes) compared
to the M/A protocol
(73.7 minutes). This
QI project identified
an opioid sparing
protocol for pediatric
T&As utilizing
dexmedetomidine
and ketorolac that
provides effective
analgesia without
increasing recovery
times or reoperative
rates.

Chi-squared
tests were used
to determine
significance of
categorical
data measured.
Odds ratios
with

There were no
differences in PONV
rates between the
baseline and final
phase (p = 0.31, OR
= 1.18, 95% CI =
0.59-2.33) or
between the early

V-B

confidence
intervals were
used to further
measure the
strength of
association.

Summon #3
Neff, 2018

To determine
association
between
propofol
shortage and
prevalence of
PONV in the
postoperative

None

A
retrospective
observational
study

Data was
retrieved from
anesthesia
database
(Centricity,
GE
Healthcare)
which
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Statistical
analysis was
performed
using SAS
version 9.3
(SAS
Institute).
Kolmogorov-

and final phase (p =
0.13, OR = 1.60,
95% CI = 0.84-3.07).
In appropriately
treated patients, rates
of PONV in the final
phase compared with
the early phase (p =
0.044, OR = 2.13,
95% CI = 0.95-4.85).
Following the initial
Apfel scoring
training, the
proportion of
appropriately
medication patients
increased; 47% of
baseline cases, 67%
of early cases, and
59% of final cases
were appropriately
medicated (p =
0.006)
Patients during the
propofol shortage
experienced a
statistically shorter
emergence time,
higher incidence of
PONV, greater need
for rescue

III-A

phase of care
despite
administration
of antiemetic
therapy.

contains all of
the
electronically
recorded
anesthesia
history and
physical data,
intraoperative,
and PACU
data, and
postoperative
follow-up
information.
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Smirnov tests
demonstrated
that all the
continuous
variables were
skewed;
KruskalWallis tests
were used to
compare these
data, and
Pearson χ2
with Fisher
exact tests
were used to
compare the
categorical
data between
groups.

antiemetics, and
longer duration of
stay in the PACU.
Patients had a 2-fold
increase in the odds
of having PONV
during the shortage
(OR = 2.3; 95% CI =
1.5-3.5; p < 0.001)
when adjusted for all
other risk factors.
The potential
influence of
prophylactic
antiemetics on the
outcome was studied
which showed that
antiemetics
moderated the
association between
gender and PONV
(OR = 1.3; 95% CI =
0.9-1.9; p = 0.128)
but did not change
the effect of the
shortage (OR = 2.2;
95% CI = 1.4-3.5; p
< 0.001).

Summon #4
O’ReillyShah, 2018

To determine
the ED50 and
the time of
onset of
intrathecal
hydromorphone
for laboring
epidural.
IV – dose of
hydromorphone
DV – pain
score
DV – time of
onset

None

Single-center
clinical trial

Visual analog
pain scores
were used to
determine
pain. A
baseline 12 μg
were
administered
intrathecally
once the
combined
spinalepidural
catheter was
placed. If pain
was greater
than a 3 out of
10 at 30
minutes
following
initial dose,
the
subsequent
dose was
increased by 2
μg. If the pain
was less than
a 3 out of 10
at 30 minutes,
the
subsequent
63

Dixon and
Massey’s upand-down
method was
utilized to
calculate the
ED50. Among
those for
whom the
drug was
effective, the
median time to
effectiveness
was
calculated.

20 participants were
enrolled. 9 reported
pain scores less than
3 out of 10 at 30
minutes. Based on
these results, the
ED50 was determined
to be 10.9 μg 95% CI
[5.6-16.2 μg]. The
median time to onset
of pain relief was
calculated at 24
minutes (range of 1429 minutes). Only
one baby had an
Apgar score of less
than 7 and all babies
had Apgar scores
greater than 8. None
required intubation
or ventilation greater
than 5 minutes.

II-B

dose was
decreased by
2 μg.

Summon #5
Tran, 2021

To evaluate the
impact of an
injectable
opioid shortage
in a facility
with opioid
prescribing
guidance on
management of
postoperative
pain, pain
medication use,
and safety. DV
– the
proportion of
total shortacting IV
opioid doses
used for
postoperative
pain,
proportions of
individual

None

Single-center
retrospective
cohort study

Pain scores
were assessed
and recorded
by PACU
nurses prior to
administration
of pain
medications.
Data were
extracted
through the
electronic
health record,
using the
Veterans
Affairs
Informatics
and
Computing
Infrastructure.
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For statistical
analysis, the χ2
or the Fisher
exact tests
were used for
nominal data,
and the MannWhitney Utest was used
for
nonparametric
continuous
data.

The proportion of
total IV opioid doses
was lower in the
post-shortage cohort
versus the preshortage cohort
(16.6% versus
20.5%; p < 0.01).
Specific medications
used were
significantly
different between the
cohorts. The
proportion of severe
pain scores were
lower in the postshortage cohort
versus the preshortage cohort
(55.6% versus
58.5%; p = 0.04). No
significant
differences were

III-A

Summon #6
Wu, 2019

short-acting
opioids and
adjunctive
nonopioid
analgesic doses
administered,
subjective pain
scores, 30-day
mortality, need
for emergent
opioid reversal,
respiratory
depression,
hospital length
of stay, and
opioid
equivalent
doses.
To compare
standard care of
remifentanil
infusion versus
alternative care
(clinician
preference) on
postoperative
pain,
intraoperative
opioid
requirements,
postoperative

seen in the overall
proportion of
nonopioid analgesic
use, 30-day
mortality, respiratory
depression, need for
emergent opioid
reversal, hospital
length of stay, or
opioid equivalent
doses between
cohorts.

None

Single-center
retrospective
cohort study

Morphine
milligram
equivalents
for opioid
requirements.
11-point
numerical (010) rating
scale for pain.
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Retrospective
analysis of
cases assessed
total amounts
of remifentanil
or opioids
used and
converted all
doses to
morphine
milligram
equivalency
for

Mean total MMEs
for the standard care
period was 54 (95%
CI = 51-56) and 58
in the alternative care
period (95% CI = 5264). The association
between study period
and total opioids
received was not
significant (p = 0.3).

III-B

opioid
requirements,
and total opioid
requirements.
IV –
remifentanil
infusion or
Clinician
Preference
DV –
Intraoperative
opioid
requirements,
postoperative
opioid
requirements,
total opioid
requirements,
postoperative
pain

comparison of
intraoperative,
postoperative,
and total
opioid
requirements.
The
distribution of
these results
was skewed
right due to a
majority of
patients
receiving no
postoperative
opioids. As a
result,
multivariable
logistic
regression
accounting for
covariates like
age, gender,
operative time,
body mass
index, ASA,
surgical
procedure
type,
intraoperative
acetaminophen
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During the standard
care period (31
MME), patients
received 7.5 less
intraoperative MME
than those in the
alternative care
period (39 MME) (p
< 0.001).
During the standard
care period the
postoperative MME
was 20. During the
alternative care
period the
postoperative MME
was 15. Patients in
the alternative care
were less like to
require postoperative
opioids OR = 0.62
(95% CI = 0.39 –
1.00, p = 0.50).
Maximum
postoperative pain
score during the
standard care period
was 5.9 and during
the alternative care

administration,
administration
of lidocaine,
and
intraoperative
narcotics.
Multivariable
linear
regression
adjusting for
previously
mentioned
covariates
when
assessing: 1.
The
association
between
remifentanil
and the need
for PONV
rescue
medication. 2.
The
association
between
remifentanil
and maximum
pain score
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period it was 5.8.
This finding was not
significant (95% CI
= -0.66 – 0.38, p =
0.6).
Postoperative nausea
and vomiting were
not significant
between the two
study periods (p =
0.99).
Postoperative
discharge time was
not significant
between the two
study periods (p =
0.7).

Multivariable
linear
regression
adjusted for
surgical start
time to test the
association
between
remifentanil
and discharge
time.
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Table 3
Directed Content Analysis
Code

Anesthesia delivery commonly
impacted by drug shortages

Citations
(Full citation in
references)
AANA (2019)
Greenberg et al. (2015)
Meyer (2019)
Neff et al. (2018)

Limited alternatives may exist

Neff et al. (2018)
O’Reilly-Shah et al.
(2018)

Shortages lead to adverse events
and/or worse patient outcomes

AANA (2019)
Geisz-Everson et al.
(2019)
Greenberg et al. (2015)
ISMP (2018)
Mariano (2018)
Meyer (2019)

Educational Component
• Anesthesia and pain medications are two of the most common
classes of drugs affected (AANA, 2019)
• Despite governmental and provider organization support to
reduce drug shortages, they appear to be on the rise
(Greenberg et al., 2015)
• 97.6% of anesthesiologists experienced a drug shortage in
their practices in the past year. (Meyer 2019)
• The use of inhaled anesthetics during a propofol shortage led
to a doubling of postoperative nausea and vomiting, greater
need for antiemetics, and longer postoperative recovery (Neff
et al., 2018)
• During a nationwide propofol shortage, there was limited
alternatives for total intravenous anesthesia at an outpatient
surgery center. (Neff et al., 2018)
• There are limited number of preservative-free narcotics that
are efficacious for laboring parturients (O’Reilly-Shah et al.,
2018)
• Drug shortages lead to increased morbidity and mortality,
rationing of drugs, administering second-line medications that
may be less effective, increased length of hospitalization, or
transfer of patients to another facility that has the drug in
stock (AANA, 2019)
• During a shortage, less familiar modalities may be
implemented potentially leading to risk of patient harm due to
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Neff et al. (2018)
O’Reilly-Shah et al.
(2018)
Phuong et al. (2019)
Tucker et al. (2020)
GAO (2016)
Vail et al. (2017)

unfamiliarity or inexperience with technique, variability of
patient response, or interaction with other medications
(AANA, 2019)
• An unfamiliar induction drug was administered and resulted
in the patient having a cardiac event resulting in an anoxic
brain injury. It was determined that the CRNA was unfamiliar
with the medication and did not dilute it appropriately prior to
administration (Geisz-Everson et al., 2019)
• Edrophonium can replace neostigmine, however, cardiac
patients are particularly susceptible to the side effects of
edrophonium/atropine combination (Greenberg et al., 2015)
• Examples of errors as a result of drug shortages: An ampule
of sufentanil was administered in lieu of fentanyl during a
fentanyl shortage; 1 ml vials of morphine 10 mg was
dispensed when 2 mg vials were unavailable, 10 mg were
administered; epinephrine 1 mg per ml was used to prepare
and administer an IV dose, however, the drug was not diluted
and the wrong dose was administered. Multiple dose vial of
bupivacaine with a preservative was used for an epidural
when preservative free bupivacaine with epinephrine was
unavailable; anesthesia staff attempted to make their own
bupivacaine with epinephrine 1:200,000 by adding
epinephrine to plain bupivacaine resulting in variable
concentrations (ISMP, 2018).
• Shortages in local anesthetics results in either a second-line
anesthetic being chosen or the increased administration of
narcotic for intraoperative and postoperative pain when
regional anesthesia is preferred (Mariano, 2018)
• 30-day mortality is lower for patients who receive regional
anesthesia compared to those who receive general anesthesia.
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Disruptions in local anesthetic supply can result in increased
mortality in this population (Mariano, 2018).
• One strategy to mitigate the risk of chronic post-surgical pain
is the utilization of regional anesthesia. If regional blockade is
not performed, patients are at an increased risk of pain and
higher opioid requirements with a significant risk of
developing chronic postoperative pain. When regional
anesthesia cannot be administered due to shortages of local
anesthetics, patient outcomes can worsen (Mariano, 2018).
• Using alternative agents during a drug shortage result in
adverse events and medication errors that lead to patient harm
(McLaughlin et al., 2013).
• Half of respondents to an ISMP survey indicated that patients
received a less effective drug (Meyer, 2019)
• The use of inhaled anesthetics during a propofol shortage led
to a doubling of postoperative nausea and vomiting, greater
need for antiemetics, and longer postoperative recovery
despite a mitigation strategy (Neff et al., 2018)
• There are limited preservative free options suitable for
intrathecal administration. Assessment of intrathecal
hydromorphone was proposed to assess efficacy for labor
pain. Hydromorphone cannot be recommended based on the
prolonged onset of action (O’Reilly-Shah et al., 2018)
• Of the 38 articles retrieved, 10 reported increased mortality,
14 reported increased adverse drug reactions, 8 reported an
increase in medication errors, 7 studies reported increased
hospitalization (Phuong et al., 2019)
• Many studies assessing patient outcomes and adverse events
are derived from survey data from healthcare professionals.
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Medication shortages leads to
increased mortality

AANA (2019)
Phuong et al. (2019)
Vail et al. (2017)

Alternative drugs may be less
efficacious or less desirable than
first-line drugs

AANA (2019)
Hamel et al. (2018)
Meyer (2019)
Neff et al. (2018)
Tucker et al. (2020)
GAO (2016)
Vail et al. (2017)

The true effects of drug shortages are not fully known and are
likely underreported (Tucker et al., 2020)
• Shortages continue to affect provider’s ability to safely care
for patients (GAO, 2016)
• The use of second-line vasopressor (phenylephrine) during a
norepinephrine shortage resulted in a 3.7% increase of inhospital mortality (Vail et al., 2017)
• A norepinephrine shortage during 2008 to 2013 found a 3.7%
increase in mortality in patients with septic shock when
phenylephrine was used as the first-line agent (Vail et al.,
2017; AANA, 2019; Phuong et al., 2019).
• Of the 38 articles retrieved, 10 reported increased mortality
(Phuong et al., 2019)
• Drug shortages lead to increased morbidity and mortality,
administering second-line medications that may be less
effective, and increased length of hospitalization (AANA,
2019)
• Hydromorphone has gone into shortage resulting in the use of
the second-line agent, morphine. Morphine, however, has
gone into shortage resulting in some hospitals relying on a
third-line agent, meperidine which has been removed from
many hospital formularies and is prone to adverse events and
side effects (AANA, 2019).
• During opioid shortages, cancer patients may receive
multimodal pain modalities in lieu of potent narcotics
(AANA, 2019).
• Pyridostigmine, an alternative to neostigmine, takes
significantly longer to reverse neuromuscular blockade and
produces more cardiovascular effects which makes less ideal
(Hamel, 2018)
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Medication shortages lead to
increased medication errors

• 71% of respondents to an ISMP survey indicated that they
were unable to provide patients with the recommended drug
or treatment and approximately half noted that patients
received a less effective drug (Meyer, 2019)
• The use of an inhaled anesthetic during a propofol shortage
led to a doubling of postoperative nausea and vomiting,
greater need for antiemetics, and longer postoperative
recovery (Neff et al., 2018)
• Nearly all hospitals experience drug shortages and providers
regularly treat patients with alternative agents. These
shortages have put patients at risk of poor health outcomes
(Tucker et al., 2020)
• When available supplies of drugs are insufficient, patient care
may be adversely affected (GAO, 2016)
• Norepinephrine is recommended as the first-line vasopressor
for the treatment of hypotension induced by septic shock. In
substituting for a second-line agent, phenylephrine, there
were significant impacts on mortality outcomes for patients
(Vail et al., 2017).
• Less familiar modalities potentially lead to patient harm due
to unfamiliarity or inexperience with technique, variability of
patient response, or interaction with other medications
(AANA, 2019)
• Medication errors are more likely to occur when the
pharmacy must change how a drug is prepared, packaged, or
dispensed (AANA, 2019)
• Clinicians must abruptly change their practice with little or no
notice (AANA, 2019)

AANA (2019)
ISMP (2018)
Phuong et al. (2019)
Tucker et al. (2020)
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Healthcare providers may be
unfamiliar with alternative agents

• Errors include errors of omission, wrong dose dispensed or
administered, wrong frequency, wrong route, and wrong
indication (AANA, 2019).
• Substitute medications have different concentrations and
potencies than first-line therapy predisposing to error
(AANA, 2019)
• 21% of respondents to an ISMP survey were aware of the
occurrence of at least one medication error related to a drug
shortage in the 6 months prior to the survey (ISMP, 2018).
• Of the 38 articles retrieved, 10 reported increased mortality,
14 reported increased adverse drug reactions, 8 reported an
increase in medication errors, 7 studies reported increased
hospitalization (Phuong et al., 2019)
• Survey data showed substantial impact including numerous
errors and death. Current data from centralized reporting
system is lacking (Tucker et al., 2020)
• Less familiar modalities potentially lead to patient harm due
to unfamiliarity or inexperience with technique, variability of
patient response, or interaction with other medications
(AANA, 2019)
• Medication shortages may require a anesthesia providers to
use an unfamiliar drug or an unfamiliar concentration of drug.
This unfamiliarity constitutes a patient safety threat (GeiszEverson, 2019).
• Edrophonium and atropine is an alternative during
neostigmine shortage, however, many anesthesia providers
may be unfamiliar with the dosing, pharmacokinetics, and
side effects of this combination (Greenberg et al., 2015).
• An increased risk of medication errors can result when using
different drugs due to clinician unfamiliarity (Meyer, 2019)

AANA (2019)
Geisz-Everson et al.
(2019)
Greenberg et al. (2015)
Meyer (2019)
Phuong et al. (2019)
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Drug shortages are a frequent
occurrence

• Drug shortages are associated with increased medication
errors, mainly attributable to unfamiliarity (Phuong et al.,
2019)
• Anesthesia-related drug shortages, which have been persistent
since 2007, strongly impact quality of anesthesia delivery
(AANA, 2019)
• FDA has reported an increase in drug shortages from 61 in
2005 to 178 in 2010 (Hsia et al., 2015)
• Most respondents to an ISMP survey confirmed drug
shortages continue to be a daily struggle with an increasing
number of lifesaving drugs affected (ISMP, 2018)
• 55% of respondents reported more than 20 drugs were
involved in shortages during the 6 months prior to the survey
(ISMP, 2018)
• Most respondents were affected by at least one drug shortage
daily (ISMP, 2018)
• There are limited number of preservative-free narcotics that
are efficacious for laboring parturients (O’Reilly-Shah et al.,
2018)
• Medication shortages have been described as a growing
world-wide issue (Phuong et al., 2019)
• Shortage of injectable opioids are common and have the
potential to adversely affect patient care (Tran et al., 2020)
• Drug shortages have become the norm in the United States.
The median duration of shortage is over a year (Tucker et al.,
2020)
• The number of new drug shortages has declined since 2011,
the number of ongoing shortages remains high due to
increased duration of the drug in shortage (GAO, 2016)
•

AANA (2019)
Hsia et al. (2015)
ISMP (2018)
O’Reilly-Shah et al.
(2018)
Phuong et al. (2019)
Tran et al. (2021)
Tucker et al. (2020)
GAO (2016)
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Drug shortages are a frequent
occurrence: Numerous specialty
areas are impacted by drug
shortages

ASHP (2017)
ISMP (2018)

Quality Concerns: Poor
manufacturing quality leads to
shortages

AANA (2019)
ASHP (2017)
Fox et al. (2017)
Greenberg et al. (2015)
Legaspi (2020)
Mariano (2018)
Meyer (2019)
Phuong et al. (2019)
GAO (2016)

• Shortages involving widely used products like saline impact
nearly every area of the hospital and acute care centers
(ASHP, 2017)
• Shortages were reported across all specialty areas (ISMP,
2018)
• No specialty area remains unaffected by drug shortages.
Shortages were reported across all treatment categories.
Over two-thirds of respondents reported shortages that
impacted emergency care (87%), anesthesia care (85%),
pain management (81%), infectious disease treatment (71%),
and cardiovascular care (68%) (ISMP, 2018)
• Quality problems in manufacturing and raw material are
consistent themes in drug shortages (AANA, 2019).
• When a quality concern is noted, the product line is halted
until fixed. When a drug product line that has few competitors
shuts down, demand can quickly outpace supply (ASHP,
2017)
• Key reasons for drug shortages are poor manufacturing
quality and a lack of production capacity (Fox et al., 2017).
• Raw material shortages, manufacturing control issues,
industry consolidation, and manufacturing discontinuation
(Greenberg et al., 2015)
• Foreign manufacturing facilities are inspected for Current
Good Manufacturing Process (CGMP); however, quality of
drugs is not inspected (Legaspi, 2020)
• Following a merger, a major facility shutdown due to quality
concerns which led to an acute shortage of medications
(Mariano, 2018)
• Poor manufacturing quality account for the majority of
shortages over the last 6 years (Meyer, 2019)
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Sterile injectable drugs are most
commonly in shortage

• Non-sterility due to bacterial or fungal contamination;
retained particulate matter such as glass, metal, or fiber in
vials; crystallization; precipitation; impurities; degradants
leading to less effective drug; and equipment failures (Meyer,
2019).
• Poor quality manufacturing issues, insufficient quantities of
raw materials, regulatory issues, discontinuation of product,
procurement issues, business decisions, and natural disasters
(Phuong et al., 2019)
• Increasing number of manufacturers slowing or halting
production to address quality issues (GAO, 2016)
• Anesthetics and pain medications are two of the most
common classes of drugs affected (AANA, 2019)
• Drug shortages primarily affect generic, sterile injectable
products (ASHP, 2017)
• Only one to two manufacturers make the vast majority of
injectables. Supply disruption can quickly lead to drug
shortages (Meyer, 2019)
• 46-55% of sterile injectable cardiovascular drug shortages
between the years of 2012 and 2014 were from manufacturing
facilities that had received an FDA warning letter because
they failed to comply with manufacturing standards (Meyer,
2019)
• Potential serious implications of an injectable opioid shortage
may include undertreated pain, longer hospitalization, higher
healthcare costs, and medication errors (Tran et al., 2020)
• Shortage of injectable opioids are common and have the
potential to adversely affect patient care (Tran et al., 2020)
• The FDA has issued an increasing number of warning letters
to sterile injectable drug manufacturers (GAO, 2016)

AANA (2019)
ASHP (2017)
Meyer (2019)
Tran et al. (2021)
GAO (2016)
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Few manufacturers or singlesource suppliers lead to
medication shortages

Fox et al. (2017)
Hamel et al. (2018)
Meyer (2019)

Regulatory Factors

Fox et al. (2017)
Greenberg et al. (2015)
Hamel et al. (2018)
Salajegheh et al. (2020)
Tucker et al. (2020)

• Shortages of sterile injectables was strongly associated with a
decline in the number of manufacturers and subsequent
failure of CGMP (GAO, 2016).
• 3 manufacturers held 71% of the generic injectable market.
At least 4 manufacturers are required in order to realize price
reductions (Fox et al., 2017)
• As a result of the Prescription Drug Wrap-Up program, many
manufacturers stopped making older drugs resulting in a
single source supplier (Hamel, 2018)
• Only one to two manufacturers make the vast majority of
injectables. Supply disruptions quickly lead to drug shortages
(Meyer, 2019)
• Manufacturers leaving the market due to being “unapproved”
following the approval of a generic medication by the FDA’s
Drug Wrap-Up Program (Fox et al., 2017)
• Following approval of neostigmine, many “unapproved”
manufacturers left the market resulting in shortage
(Greenberg et al., 2015)
• After manufacturers left the market, neostigmine price rose
446% from 2013 to 2015 (Hamel, 2018)
• Inpatient expenditures for neostigmine rose from $1 million
in 2013 to over $75 million in 2015 without a net increase in
volume of drug administered. The FDA application fee for
approval of neostigmine cost $2 million (Hamel, 2018)
• The Drug Enforcement Agency has reduced the allocated
product quotas of narcotic production in the United States
leading to the unintentional impact on intravenous opioid
availability for use during the perioperative period
(Salajegheh et al., 2020)
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• 36 out of 112 papers assessed indicated there are regulatory
components that lead to drug shortages (Tucker et al., 2020)
Regulatory Factors: No regulatory
authority to regulate drug pricing

Fox et al. (2017)
Tucker et al. (2020)
GAO (2016)

Lack of transparency

AANA (2019)
Fox et al. (2017)
Legaspi (2020)
Tucker et al. (2020)

• The United States has no price controls for drug products, and
suppliers may charge any price they think the market will
bear (Fox et al., 2017)
• The FDA cannot require manufacturers to maintain
redundancy, implement other continuity measures, or produce
a drug. If market-based solutions are unable to resolve a drug
shortage, further legislation may be necessary (Tucker et al.,
2020)
• FDA cannot control the prices of marketed drugs (GAO,
2016)
• Manufacturers need to increase transparency regarding
impending shortages so that facilities and providers can plan,
prepare, and review other options (AANA, 2019).
• Certain healthcare facilities may lack access to timely basic
information which can lead to asymmetric power in the
marketplace (AANA, 2019)
• Group purchasing organizations may enter into exclusive
contracts with suppliers. This may limit competition.
Specifics about group purchasing practices remains unclear
(AANA, 2019)
• Drug release dates may have a year-long range making it
difficult to adequately plan inventory (AANA, 2019).
• Drug shortage information available to healthcare providers is
ambiguous and does not provide information that helps
hospital develop meaningful solutions. Information about
medications at a particular manufacturer is considered a trade
secret (Fox 2017)
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Economic factors

• Little to no transparency from foreign drug manufacturers
(Legaspi, 2020)
• There is nearly no transparency about the manufacturing
practices and supply decisions, and the pharmaceutical
industry must be involved in preventing shortages (Tucker et
al., 2020)
• Unapproved medications, off-patent sole-source medications,
and infrequently used medications (Fox et al., 2017)
• Sole source drugs like nitroprusside can lead to
hyperinflation. Cost went from $50 a vial to about $800 per
vial (Fox et al., 2017)
• Hospitals are unable to easily recoup costs when medication
costs increase (Fox et al., 2017).
• When a company maintains all therapy options for a disease
state, inflation of cost can occur (Fox et al., 2017)
• Costs may raise prices due to increase in raw material cost,
when factory upgrades are required, business reasons related
to increasing profits. However, the motivating reason is rarely
apparent (Fox et al., 2017)
• No governmental agency or other entity can mandate a
manufacturer to continue production, maintain levels of
inventory and/or set prices of any drug (Greenberg et al.,
2015)
• Drug manufacturers must balance the needs of customers, the
marketplace, and shareholders (Greenberg et al., 2015)
• Sterile injectable drugs have low profit margins leading to
limiting infrastructure investment or manufacturers exiting
the market predispose this market to supply chain disruption
(GAO, 2016)

Fox et al. (2017)
Greenberg et al. (2015)
GAO (2016)
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Increased Costs: Hospital and
Patient

• “Just in time” inventory practices by can lead to shortages.
Manufacturers may have 2 to 3 months of inventory on hand;
a distributor/ supplier may have 1 month of inventory; a
health care facility may have just a few weeks of inventory on
hand. A shortage can result in rapid depletion of stockpiles
(GAO, 2016)
• During a shortage, medications may be purchased from an
alternative supplier but at a cost 2 to 4 times the usual cost
• During a shortage, pharmacies may have to purchase more
expensive brands, use alternative suppliers, or the secondary
market, all of which increases cost (AANA, 2019).
• Pharmacy resources are required to communicate and educate
staff on the alternatives. Repackaging vials of medications
into smaller syringes to mitigate waste increase pharmacy
labor requirements. Revising electronic health records and
protocols to reflect a substitution increases labor costs
(AANA, 2019).
• Sole source drugs like nitroprusside can lead to
hyperinflation. Costs went from $50 a vial to about $800 per
vial (Fox et al., 2017)
• Hospitals are unable to easily recoup costs when medication
costs increase (Fox et al., 2017).
• When a company maintains all therapy options for a disease
state, inflation of cost can occur.
• Following consolidation of the neostigmine market by Eclat,
they significantly raised the price of the drug (Greenberg et
al., 2015)
• The average Medicare reimbursement increases 2.7% per year
while average medication expenses have increased annually
by 24.3% (Hamel, 2018)

AANA (2019)
Fox et al. (2017)
Greenberg et al. (2015)
Hamel et al. (2018)
Mariano (2018)
Phuong et al. (2019)
Tucker et al. (2020)
Vail et al. (2017)
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Increased Costs: Hospital Labor

• Regional anesthesia helps to mitigate pain in certain
procedures. Shortages of local anesthetics used in regional
anesthesia contribute to longer admissions, rates of
readmissions, delay rehabilitation due to inadequate pain
control (Mariano, 2018).
• Institutions reported a 300-500% increase in cost for drugs in
shortage; Individual drugs can experience a 1704% increase
in cost (Phuong et al., 2019)
• Nationally, labor costs amount to $359 million annually to
manage drug shortages. These costs are increasing (Tucker et
al., 2020)
• Drug shortages are an increasing problem with potential
effects on patients and healthcare delivery costs (Vail et al.,
2017)
• Additional pharmacy resources are required: to communicate
and educate staff on the alternatives; repackage vials of
medications into smaller syringes to mitigate waste; revise
electronic health records and protocols to reflect substitution
(AANA, 2019).
• When a shortage occurs, many hours are spent making
changes to the electronic health record (ASHP, 2017).
• The staff hours spent planning for the shortage; educating
staff; restocking and bracoding alternative products; dealing
with secondary market vendors; prescribing, preparing, and
administering unfamiliar products; and fielding questions
consumes a large portion of health professionals’ time (IMSP,
2018)
• Many ISMP survey respondents felt as though full-time hours
were required to manage drug shortages and felt as though

AANA (2019)
ASHP (2017)
ISMP (2018)
Tran et al. (2021)
Tucker et al. (2020)
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Natural disasters/events lead to
shortages

AANA (2019
Meyer (2019)
Phuong et al. (2019)

National Security Concerns

ASHP (2017)
Legaspi (2020)
Meyer (2019)
Tucker et al. (2020)

managing drug shortages had cut into providing patient care
(ISMP, 2018)
• Pharmacists are tasked with notifying the prescriber that the
patient met IV to oral conversion. While necessary,
implementation of this protocol during a period of
intravenous opioid shortage added an additional workflow
onto pharmacists. (Tran et al., 2020)
• During times of shortages when alternative agents are
utilized, a change to automated processes can consume
significant time (Tucker et al., 2020)
• Collectively, health systems spend millions of hours annually
to manage shortages (Tucker et al., 2020)
• Hurricane Maria affected 80 manufacturing facilities that
produce 7 of the top 10 drugs globally. Ninety products
including intravenous normal saline were affected by
Hurricane Maria. 10% of all U.S. drugs are made in Puerto
Rice Natural disasters are unlikely to decrease and
preparations should be made to strengthen the supply chain
(AANA, 2019; Meyer, 2019).
• Hurricanes, fires, tornadoes, tsunamis, and floods can play an
additional role of not only destruction of the raw material but
also damage to the raw material facility and obstruction of
product transportation (Phuong, et al., 2019)
• When a drug goes into shortage, it impacts the U.S. military
and VA medical centers (ASHP, 2017).
• 72% of active pharmaceutical ingredient manufacturers are
foreign with 13% coming from China (Legaspi, 2020)
• Foreign facilities are inspected for CGMP, the drugs
themselves are not inspected for quality (Legaspi, 2020).

83

Large reliance on foreign
countries for manufacturing of
pharmaceuticals or active
pharmaceutical ingredients
Ethical Considerations: Patient
Informed Consent

• The American Medical Association has requested that the
Department of Health and Human Services examine the
problem of drug shortages in the context of a national security
initiative (Meyer, 2019).
• Manufacturing sites could be evaluated as part of national
security or essential infrastructure (Tucker et al., 2020)
• 72% of active pharmaceutical ingredient manufacturers are
foreign with 13% coming from China (Legaspi, 2020)
• Foreign facilities are inspected for CGMP, the drugs
themselves are not inspected for quality (Legaspi, 2020).
• Informing patients of drug shortages may increase their fear
and anxiety prior to surgery. Therefore, this disclosure needs
to be reviewed carefully and critically (Greenberg et al.,
2015)
• 76.2% of patients wanted to be informed by their
anesthesiologist about a drug shortage if there were “slight”
differences between the first-line drug and second-line drug
(Hsia et al., 2015)
• In addition, 73.2% of patients wanted to be informed if there
were even “very slight” difference – comparable to the
differences between acetaminophen and aspirin for treating a
headache.
• 39.7% would continue to proceed with surgery and not
postpone. These findings raise an ethical concern about
informed consent by patients during times of shortages and
their willingness to proceed with surgery (Hsia et al., 2015).
• Patients may be largely unaware that shortages occur. This
unfamiliarity makes shared decision-making difficult and
limits public support for policies to reduce shortages (Tucker
et al., 2020)

Legaspi (2020)

Greenberg et al. (2015)
Hsia et al. (2015)
Tucker et al. (2020)
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Strategies to mitigate shortages

• Develop a drug supply management policy and procedure
detailing how facilities will identify shortages, communicate
these shortages with anesthesia staff, and how the shortage
will be addressed (AANA, 2019)
• Monitor drug availability and identify any sudden shortages
(AANA, 2019)
• Educate anesthesia staff on new practice changes with
substitution of drug with an alternative or of new
concentration or supplier (AANA, 2019)
• Consider compounding drug in shortage in the hospital
pharmacy if hospital is 503b compliant (AANA, 2019)
• Early notification of discontinuances and interruptions has
helped to mitigate the impact of drug shortages (ASHP,
2017).
• Manufacturers could provide the FDA with more information
about the causes of the shortages and their expected duration
(ASHP, 2017)
• Establish best practices for high-alert medications. (ASHP,
2017)
• FDA should mandate manufacturers establish contingency
plans or redundancies (ASHP, 2017)
• FDA should incentivize manufacturing of a drug when it goes
into shortage (ASHP, 2017).
• FDA should provide additional information on the quality of
the outsourced compounding via 503b facilities (ASHP,
2017)
• Enhance provisions of title X of FDASIA to disclose the
location of production of medications (ASHP, 2017)
• Efforts could be made by the U.S. Health and Human
Services and Department of Homeland Security to improve

AANA (2019)
ASHP (2017)
Mariano (2018)
Meyer (2019)
Salajegheh et al. (2020)
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supply chain resilience during emergency situations (ASHP,
2017)
• Request electronic health record vendors make switching
products easier to reduce labor burden (ASHP, 2017)
• Incentivize manufacturers to improve quality (ASHP, 2017).
• Assess for potential drug shortages that occur as a result of a
merger and subsequent consolidation of product lines (ASHP,
2017)
• Have up to date information regarding current inventory
(Mariano, 2018)
• Avoid excessive medication waste (Mariano, 2018)
• Find opportunities for pharmacy to split commercially
prepared large vials into single-dose syringes (Mariano, 2018)
• If the anesthesia provider determines the risk of using a less
desirable agent to be significant, a discussion of alternative
plans including cancellation/delay of case should occur
(Mariano, 2018)
• Hospitals develop partnership to manufacture their own drugs
(Mariano, 2018).
• Raise awareness to the general public about the incidence of
drug shortages and place pressure on legislatures (Mariano,
2018)
• Ration drugs; establish criteria for use; change par levels on
automated dispensing cabinets; remove inventory to
automated dispensing cabinets; purchase more expensive
products; borrow or purchase from another health system;
purchase different strengths/concentrations; compound
unavailable drug in-house (Meyer, 2019).
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• Develop protocol to mitigate reliance on intravenous opioids
with a focus on enteral opioids, non-opioid analgesia, and
neuraxial and regional anesthesia (Salajegheh et al., 2020)
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Table 4
Expert Content Validity Scores (N=12)
Anesthesia Drug Shortages: Safety Threats
Content of Teaching Plan
1. Anesthesia Drug Shortages: Safety Threats
Anesthesia Medications
● Anesthetics & pain medications are commonly in shortage
● Increased morbidity and mortality
● Limited alternative options
● Few preservative-free options available
● Current Shortages
2. Anesthesia Drug Shortages: Safety Threats
Patient Safety
● Increased medication errors
● Worse side effect profile
● Increased risk of chronic pain
● Untreated/Undertreated pain
● Delays or cancellations of care
● Increased length of hospitalization
3. Anesthesia Drug Shortages: Safety Threats
Professional Concerns
● Centralized data are currently lacking
● Unfamiliarity with alternative agents
● Abrupt change to well-established practice
4. Shortages Are Frequent Occurrence
● Anesthesia drug shortages persistent
● Shortages persist despite systemic changes
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S-CVI/Ave = 0.88
4-Point Scale
I-CVI
0.92

Validity Met/Not met
Item Accepted/Revised/Rejected

0.83

Met/Accepted

0.83

Met/Accepted

0.92

Met/Accepted

Met/ Accepted

● The duration in which drugs remain in shortage has increased
over time
● Increase number of drugs in shortage
● Specialty areas frequently impacted by shortages
5. Quality Concerns for Manufacturers and Providers of
Medications
● Poor manufacturing environment
● Poor quality raw materials
● Few manufacturers
● Halt/Delay in manufacturing
● Foreign drugs not inspected
● Consolidation of market
● Non-sterility due to contamination of medication vials (e.g.,
bacterial growth, foreign item in vial)
6. Sterile Injectable Drug Problems
● Commonly in shortage
● Few manufacturers
● Shortages of sterile injectable drugs are a large burden on
hospitals
● Frequently used in anesthesia delivery
7. Manufacturers/Single Source
● Generic market has few manufacturers
● FDA Prescription Drug Wrap-Up Program: approval process
for medications manufactured before 1962
o Unapproved preparations of drugs no longer
manufactured
o Led to single suppliers of common medications
● Single subcontractor supplies multiple manufacturers
● Supply disruptions quickly lead to shortage
8. Regulatory Factors: Federal
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0.80

Met/Accepted

0.83

Met/Accepted

0.90

Met/Accepted

1.00

Met/Accepted

● Prescription Drug Wrap-Up Program
● Hyperinflation due to market factors, e.g., Neostigmine cost
increasing by 446% in a period of two years.
● Drug Enforcement Agency decreased allocated product
quotas of narcotics in response to opioid epidemic
● Prices reflective of market forces
● No price controls
9. Lack of Transparency in Shortages
● Poor transparency in manufacturing disruption
● Hospitals may lack access to timely information
● Limited transparency into foreign manufacturers.
o Good manufacturing processes (CGMPs) do not
account for manufacturing processes above minimum
o Could lead to preventing drug supply disruption;
market competition based solely on cost
● Reasons for shortages not frequently disclosed
● Duration of expected shortage not specific
10. Economic Factors for Manufacturers and Health Care
Systems Centers
● Prescription Drug Wrap-Up Program
● Sole source medications
● Fixed rate hospital reimbursements
o Average medication expenses increased annually by
24.3%; reimbursement for procedure or
hospitalization not reflective of pharmaceutical market
demands
● Single supplier for a given disease
● Low profit margins
● Just in time inventory practices leads hospitals to have limited
stockpile of excess drug
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0.83

Met/Accepted

0.80

Met/Accepted
See comments in the Results section

11. Hospital & Patient Costs
● Higher costs for hospitals & patients
● Higher costs of alternatives
● Increased labor costs
● Longer hospitalization
● Drug price inflation outpacing hospital reimbursement
12. Natural Disasters
● Consolidation of manufacturing into one geographic area
increases risk during a natural disaster
● Destruction of raw materials
● Disrupted transportation of drugs
13. National Security Concerns
● Reliance on foreign countries for active pharmaceutical
ingredients
● Foreign manufacturer inspection not robust
● United States military and Veterans Administration hospitals
vulnerable to shortages
● Trade susceptible to political unrest
● Quality control impacts active pharmaceutical ingredients
14. Ethical Considerations
● Patients are poorly informed
● Patients prefer to be informed
● Delays/Cancellations to care
15. Policy and Procedure Development
● Develop hospital-based drug supply management policy
● Establish criteria for use of drug in shortage
● Change par levels in automated dispensing cabinets
● Monitor drug availability
● Daily assessment of inventory
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0.83

Met/Accepted

0.82

Met/Accepted
See comments in the Results section

0.82

Met/Accepted

0.83

Met/Accepted
See comments in the Results section

0.92

Met/Accepted

● Protocol development for substitution of enteral opioids for
intravenous administration
● Policy development for delay/cancelling elective surgeries
16. Pharmacy Based Interventions
● Change par levels in automated dispensing cabinets
● Ration drugs
● Purchase more expensive product/alternative concentrations
● Compound shortage drugs in-house
17. Quality Improvement Hospitals
● Work with electronic health record vendor to quickly change
drug concentration/brand
● Divide larger vials into single-dose syringes
18. Best Practices Anesthesia Providers Drug Shortages
● Educate anesthesia staff on new practice changes/alternatives
● Develop departmental strategy to communicate problems with
Pharmacy and Pharmacy and Therapeutics Committee
● Avoid waste
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1.00

Met/Accepted

1.00

Met/Accepted

1.00

Met/Accepted

Table 5
Expert Reviewers’ Constructive Comments
Item
1. Anesthesia Drug Shortages: Safety Threats
Anesthesia Medications
• Anesthetics & pain medications are commonly in
shortage
• Increased morbidity and mortality
• Limited alternative options
• Few preservative-free options available
2. Anesthesia Drug Shortages: Safety Threats
Patient Safety
• Increased medication errors
• Worse side effect profile
• Increased risk of chronic pain
• Untreated/Undertreated pain
• Delays or cancellations of care
• Increased length of hospitalization

Comment
• Consider the change of medication packaging. A
frequent issue is a new vendor providing a substitute
medication during a backorder, that looks identical to
completely different medication. Then, pharmacy may
replace this medication in the Omnicell drawer next to a
lookalike. This issue is often made more dangerous
when we are not notified.
• Information impacts direct patient care at the bedside.
•

Highly relevant to understand the background—but
needs more explanation. Would extend the time a few
minutes for this content and use other methods of
instruction (case studies?) Helping to create a sense of
urgency (Why this is important to anesthesia
providers)—and the knowing of which (as stated below)
what is needed to assimilate the content on strategies
While I would believe that shortages add risk-- Not
clear on what these errors are—omissions? Wrong drug
swaps? Wrong dose because of new brand with
unexpected concentration? Dilution error? Would be
hard to “quantify” as “increased”—what is that based
on?
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I would want you to be specific about the risk these
shortages present. Only when you know the cause of the
risk can you plan effective strategies

•

3. Anesthesia Drug Shortages: Safety Threats
Professional Concerns
• Centralized data is currently lacking
• Unfamiliarity with alternative agents
• Abrupt change to well established practice

“Worse” side effect profile— “worse” than what?
Increasing side effect frequency or severity? Do you
mean delay or cancellation of procedures? (vs care?)
Having trouble with understanding Objective 3.
“information deficient of information?” Are you
speaking of lack of patient information? Lack of drug
shortage information?
Centralized information on drug shortages is not
established?
Lack of communication channels (daily changes) of
drug shortages that impact anesthesia practice?
Unexpected changes to drug, dose, and concentration or
unknown hazard profile when new drugs introduced?

4.
•
•
•
•
•
5.
•
•

Shortages Are a Frequent Occurrence
Anesthesia drug shortages persistent
Shortages persist despite mitigation strategies
Increase duration drugs in shortage
Increase number of drugs in shortage
Specialty areas frequently impacted by shortages
Quality Concerns for Manufacturers and Providers of
Medications
Poor manufacturing environment
Poor quality raw materials
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•

Interesting—but not as relevant as bedside providers
can do little to influence supply chain issues. More
importantly—need to know about them – anticipate how
to manage critical shortages.

•
•
•
•
•
6.
•
•
•
•
7.
•
•
•
•
8.
•
•
•

Few manufacturers
Halt/Delay in manufacturing
Foreign drugs not inspected
Consolidation of market
Non-sterility due to contamination
Sterile Injectable Drug Problems
Commonly in shortage
Few manufacturers
High burden on hospitals
Frequently used in anesthesia delivery
Manufacturers/Single Source
Generic market has few manufacturers
Prescription Drug Wrap-Up Program
Single subcontractor supplies multiple manufacturers
Supply disruptions quickly lead to shortage
Regulatory Factors: Federal
Prescription Drug Wrap-Up Program
Unintentional hyperinflation
Drug Enforcement Agency decreasing allocated product
quotas of narcotics in response to opioid epidemic
• Prices are reflective of market forces
• No price controls
9. Lack of Transparency in Shortages
• Poor transparency in manufacturing disruption
• Hospitals may lack resources to timely information
• Limited transparency into foreign manufacturers
• Reasons for shortages not frequently disclosed
• Duration of expected shortage not specific
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•

Feels repetitive and can be included in earlier content.

•

Interesting—but not in control of anesthesia providers.

•

Not as much of interest to frontline user.

•

This is not super important for novices to know, except
for the duration of expected shortage. This would be
nice for all staff who administered meds to know.

•

Helpful information but not most important.

10. Economic Factors for Manufacturers and Health Care
Centers
• Prescription Drug Wrap-Up Program
• Sole source medications
• Inflexible hospital reimbursements
• Single supplier for a given disease
• Low profit margins
• Just in time inventory practices leads to hospitals have
limited stockpile of excess drug
11. Hospital & Patient Costs
• Higher costs for hospitals & patients
• Higher cost of alternatives
• Increased labor costs
• Longer hospitalization
• Drug price inflation outpacing hospital reimbursement
12. Natural Disasters
• Consolidation of manufacturing into one geographic area
increases risk during a natural disaster
• Destruction of raw materials
• Disrupted transportation of drugs
13. National Security Concerns
• Reliance on foreign countries for active pharmaceutical
ingredients
• Foreign manufacturer inspection is not robust
• United States military and Veterans Administration
hospitals vulnerable to shortages
• Trade susceptible to political unrest
• Quality control impacts active pharmaceutical ingredients
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•

Too much in the weeds for a Novice CRNA. If a
pharmacy buyer—maybe – but not for every frontline
provider.

•

Not at all important.

•

Not at all important. Not sure you can say drug
shortages can lead to longer hospitalizations.

•

Not at all important.

•

Sterile products should be top concern for those who
administer medications. Inspections of the product at all
levels, especially before delivering of the med to the
patient. I would have classed this as # 3, quite relevant,
however the part of the military and VA hospitals don’t
seem to fit.

14. Ethical Considerations
• Patients are poorly informed
• Patients prefer to be informed
• Delays/Cancellations to care
15. Policy and Procedure Development
• Develop hospital-based drug supply management policy
• Establish criteria for use of drug in shortage
• Change par levels in automated dispensing cabinets
• Monitor drug availability
• Daily assessment of inventory
• Protocol development for substitution of enteral opioids
for intravenous administration
• Policy development for delay/cancelling elective
surgeries

•

I don’t believe patients care one iota about where the
meds come from.

•

Policy is important but not as sustainable as some other
actions.
Who is monitoring drug availability—is that the same
as Assessment of inventory—or are you thinking
someone is looking external at drug shortage issues?
Would expand beyond opioid substitution –What about
other critical agents for anesthesia use? What about
shortages of infusions e.g., sodium chloride? Shortage
of reversal agents, EPINEPHrine? What about shortage
of prefilled syringes (use a 503b provider, or have
pharmacy prepare)?

•
•

16. Pharmacy Based Interventions
• Change par levels in automated dispensing cabinets
• Ration drugs
• Purchase more expensive product/alternative
concentrations
• Compound shortage drugs in-house
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Include medication alerts in dispensing units for drug
substitutions to draw more attention to the differences esp
related to concentration variations
Create an interdisciplinary team to oversee drug
shortage issues—or establish an individual in pharmacy
to oversee and communicate to providers. Work
together to fill needs where they exist and look for
alternatives; Avoid functioning in silos regarding
decisions that impact many departments

Ration drugs: Needs more explanation—do you mean
drug conservation measures?
May or may not be more expensive—but may require
more processing by pharmacy to package and distribute
e.g., no more heparin flush prefilled syringes available
so pharmacy prepares on a robot

•

17. Quality Improvement Hospitals
• Work with electronic health record vendor to quickly
change drug concentration/brand
• Divide larger vials into single-dose syringes

Compounding may resolve shortage issue but also adds
risk.
Section important—items however need work.
First bullet- This is not a EHR vendor issue. Formulary
management in the EHT is an internal IT/pharmacy
system issue. Changes in products (and resulting
changes in NDC numbers that are required for effective
BCMA use at the bedside are done in pharmacy.
Second bullet- Divide larger vials into single-dose
syringes (You are describing a process for compounded
sterile products which is governed by USP <797>. This
by regulation should be done under the pharmacy
hood—belongs in the pharmacy section—not here)
Quality Improvement providers are concerned about
how the variation in care (drug shortages) is impacting
the outcome expected. Should be looking at tracking
rescue agent use to see if outcomes have changed or
there is a signal due to an increase in reported errors
associated with drug shortages. Maybe since you
switched manufacturers—the vial concentration is
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different and not everyone notices—thus resulting in
more respiratory depression and naloxone use?
When epinephrine in shortage—what dilution is
available and how is it used based on age and
indication? (e.g., Different instructions in crash cart for
dilution versus in the ED when used in anaphylaxis….)

•

18. Best Practices Anesthesia Providers Drug Shortages
• Educate anesthesia staff on new practice
changes/alternatives
• Develop departmental strategy to communicate problems
with Pharmacy and Pharmacy and Therapeutics
Committee
• Avoid waste

Other metrics that can be reported – e.g., Numerator: #
of reported medication errors in a month where drug
shortage was mentioned a contributing factor.
Denominator # of reported medication errors in a
month.
P&T meetings are usually monthly… this won’t work as
a strategy when shortages change day to day. This is
only informational. “Avoid waste”—idea too vague and
unless clearly understood encourages risky behaviors
unless clearly explained could result in reuse of
syringes between patients; using a common source
container to draw up multiple syringes (e.g.,
phenylephrine). Work with pharmacy to repackage into
unit of use single dose products to avoid unnecessary
waste.
Evaluate the practice of predrawing medications into
syringes in anticipation and advance of a case or
procedure until needed. (Cases cancelled/postponed –or
don’t need due to change in patient condition can result
in unnecessary waste.). E.g., Consider IV push of
medications (as appropriate e.g., some antibiotics)
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instead of utilizing mini-bags when sodium chloride in
shortage.
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Figure 1
Percentage of Hospitals Experiencing a Drug Shortage by Treatment Category

Note. Adapted from Meyer (2012).
101

Figure 2
New Drug Shortages by Year
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Note. Adapted from ASHP (n.d.).
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Figure 3
Duration of Ongoing Shortages from 2010 through 2015

Note. Adapted from GAO (2016).
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Figure 4
Expert Content Validity Form Data
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Appendix A
Draft and Final Teaching Plan

La Salle University
School of Nursing and Health Sciences
Graduate Nursing Program
Draft and Final Teaching Plan

Title of Educational Activity: Novice Anesthesia Providers’ Knowledge of Anesthesia Medication Shortages and Evidence-Based
Strategies to Mitigate Clinical Safety Threats
Teachers: Daniel Worley and Beata Zimmerman
1. Following completion of the educational intervention, the novice CRNA will identify causative factors leading to drug
shortages
2. Following completion of the educational intervention, the novice CRNA will identify strategies to mitigate drug shortages
3. Following completion of the educational intervention, the novice CRNA will become increasingly aware of patient safety
implications of medication shortages.
Purpose: Following the completion of this learning activity, participants will be able to identify causes of medication shortages,
possible adverse patient outcomes/events, several anesthesia medications currently in shortage, resources available to identify drug
shortages, strategies to mitigate drug shortages.
Objectives

Content for Each Objective

Methods of
Instruction
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Media

Time

Evaluation

Following completion of
the teaching
intervention, the novice
nurse anesthetists will:
1. Identify 3 safety
threats related to
anesthesia medications

2. Identify 3 safety
threats related to
patient safety

Anesthesia Drug Shortages:
Safety Threats
Anesthesia Medications
• Anesthetics & pain
medications are
commonly in shortage
• Increased morbidity and
mortality
• Limited alternative
options
• Few preservative-free
options available
Anesthesia Drug Shortages:
Safety Threats
Patient Safety
• Increased medication
errors
• Worse side effect profile
• Increased risk of chronic
pain
• Untreated/Undertreated
pain
• Delays or cancellations of
care

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed
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•

3. Compare 2 examples
of information deficits
of information
affecting anesthesia
providers’ practice and
patient safety

4. Describe the
characteristic patterns
of drug shortages

5. Identify 2 quality
concerns associated
with drug
manufacturing

Increased length of
hospitalization
Anesthesia Drug Shortages:
Safety Threats
Professional Concerns
• Centralized data is
currently lacking
• Unfamiliarity with
alternative agents
• Abrupt change to well
established practice
Shortages Are a Frequent
Occurrence
•

Anesthesia drug shortages
persistent
• Shortages persist despite
mitigation strategies
• Increase duration drugs in
shortage
• Increase number of drugs
in shortage
• Specialty areas frequently
impacted by shortages
Quality Concerns for
Manufacturers and Providers
of Medications
•
•

Poor manufacturing
environment
Poor quality raw materials

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed
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•
•

6. Name 2 reasons sterile
injectable drugs are
susceptible to shortage

7. Explain 2 ways
manufacturers/single
source suppliers
contribute to drug
shortages

8. Summarize 2
regulatory factors that
contribute to drug
shortages

Few manufacturers
Halt/Delay in
manufacturing
• Foreign drugs not
inspected
• Consolidation of market
• Non-sterility due to
contamination
Sterile Injectable Drug
Problems
•
•
•
•

Commonly in shortage
Few manufacturers
High burden on hospitals
Frequently used in
anesthesia delivery
Manufacturers/Single Source
•

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Generic market has few
manufacturers
• Prescription Drug WrapUp Program
• Single subcontractor
supplies multiple
manufacturers
• Supply disruptions quickly
lead to shortage
Regulatory Factors: Federal
Face-to-face
education
• Prescription Drug Wrappresentation on
Up Program
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PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

•

9. Explain 2 ways lack of
transparency
contributes to drug
shortages/health care
facilities’ ability to
react to shortages

10. List 2 economic
factors contributing to
drug shortages

Unintentional
hyperinflation
• Drug Enforcement
Agency decreasing
allocated product quotas
of narcotics in response to
opioid epidemic
• Prices are reflective of
market forces
• No price controls
Lack of Transparency in
Shortages
•

Poor transparency in
manufacturing disruption
• Hospitals may lack
resources to timely
information
• Limited transparency into
foreign manufacturers
• Reasons for shortages not
frequently disclosed
• Duration of expected
shortage not specific
Economic Factors for
Manufacturers and Health
Care Centers
•
•

Prescription Drug WrapUp Program
Sole source medications

medication
shortages

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed
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•

11. Name 2 sources of
increased cost for
hospitals

12. Identify 1 example of
a factor associated
with natural disaster
that impacts drug
shortages

Inflexible hospital
reimbursements
• Single supplier for a given
disease
• Low profit margins
• Just in time inventory
practices leads to hospitals
have limited stockpile of
excess drug
Hospital & Patient Costs
•

Higher costs for hospitals
& patients
• Higher cost of alternatives
• Increased labor costs
• Longer hospitalization
• Drug price inflation
outpacing hospital
reimbursement
Natural Disasters
•

•
•

Consolidation of
manufacturing into one
geographic area increases
risk during a natural
disaster
Destruction of raw
materials
Disrupted transportation
of drugs

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed
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13. Describe 1 national
security concern
related to drug
manufacturing

14. Explain a patientcentered ethical
concern related to drug
shortages

15. Identify 2 policy and
procedure changes that
can be implemented to
mitigate drug shortages

National Security Concerns
•

Reliance on foreign
countries for active
pharmaceutical
ingredients
• Foreign manufacturer
inspection is not robust
• United States military and
Veterans Administration
hospitals vulnerable to
shortages
• Trade susceptible to
political unrest
• Quality control impacts
active pharmaceutical
ingredients
Ethical Considerations
•

Patients are poorly
informed
• Patients prefer to be
informed
• Delays/Cancellations to
care
Policy and Procedure
Development
•

Develop hospital-based
drug supply management
policy

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed
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•

16. Name 1 action by
pharmacy staff that can
be implemented to
mitigate drug shortages

17. Identify 1 quality
improvement initiative
hospitals can undertake
to mitigate drug
shortages

Establish criteria for use
of drug in shortage
• Change par levels in
automated dispensing
cabinets
• Monitor drug availability
• Daily assessment of
inventory
• Protocol development for
substitution of enteral
opioids for intravenous
administration
• Policy development for
delay/cancelling elective
surgeries
Pharmacy Based Interventions
•

Change par levels in
automated dispensing
cabinets
• Ration drugs
• Purchase more expensive
product/alternative
concentrations
• Compound shortage drugs
in-house
Quality Improvement Hospitals
•

Work with electronic
health record vendor to

Face-to-face
education
presentation on
medication
shortages

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Face-to-face
education
presentation on

PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed
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18. Identify 1 action
anesthesia providers
can undertake to
mitigate drug shortages
at point of care

quickly change drug
concentration/brand
• Divide larger vials into
single-dose syringes
Best Practices Anesthesia
Providers Drug Shortages
•
•

•

Educate anesthesia staff
on new practice
changes/alternatives
Develop departmental
strategy to communicate
problems with Pharmacy
and Pharmacy and
Therapeutics Committee
Avoid waste

medication
shortages

Face-to-face
education
presentation on
medication
shortages
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PowerPoint® 5
Multiple choice
Presentation minutes exam to be
developed

Appendix B
Expert Analysis
Expert Content Validity Check
Directions:

Content Experts: Please critique the conceptual definition of bodywork. Type suggestions in the
space provided. Please add comments

Conceptual Definitions:
CRNA – A registered nurse who has satisfactorily completed an accredited nurse anesthesia training program and certifying
examination.
Novice – Beginners that have no experience with the situation in which they are placed. Novices are taught rules to guide
action but novices face the inability to use discretionary judgement.
Medication shortage – A supply disruption that affects how the pharmacy prepares or dispenses a medication that might
influence patient care when prescribers must use an alternative agent due to limited supply. Any given time interval when
the market experiences a negative gap between the supply and demand for a medication.
Educational intervention – An initiative to enhance the level of knowledge or understanding of a topic in the form of
educational materials and/or group-based learning.
Teaching Plan – A blueprint to achieve the goal and the objectives that have been developed. A teaching plan should
incorporate the following elements: 1) purpose, 2) statement of the overall goal, 3) list of objectives, 4) an outline of the
content to be covered in the teaching session, 5) instructional methods used for teaching the related content, 6) time allotted
for the teaching of each objective, 7) instructional resources needed, 8) method(s) used to evaluate learning.
Items/Components/Content

Content Experts: Please critique all items. Please read each item and rank the item using the
scale provided.
Use yellow highlighting to select the number on the scale. Kindly comment as you evaluate
each item.
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Save the document and the completed document email to worleyldaniel@gmail.com
You may prefer circling your responses on the 4-point scale provided. Then scan and send the
pdf of the document to worleyd1@lasalle.edu or zimmermanb3@lasalle.edu
Thank you very much.
Anesthesia Drug Shortages:
Safety Threats

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

Anesthesia Medications
• Anesthetics & pain
medications are
commonly in shortage
• Increased morbidity and
mortality
• Limited alternative
options
• Few preservative-free
options available
Anesthesia Drug Shortages:
Safety Threats

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

Patient Safety
• Increased medication
errors
• Worse side effect profile
• Increased risk of chronic
pain
• Untreated/Undertreated
pain
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•

Delays or cancellations of
care
• Increased length of
hospitalization
Anesthesia Drug Shortages:
Safety Threats

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

Professional Concerns
• Centralized data is
currently lacking
• Unfamiliarity with
alternative agents
• Abrupt change to well
established practice
Shortages Are a Frequent
Occurrence

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

•

Anesthesia drug shortages
persistent
• Shortages persist despite
mitigation strategies
• Increase duration drugs in
shortage
• Increase number of drugs
in shortage
• Specialty areas frequently
impacted by shortages
Quality Concerns for
Manufacturers and Providers
of Medications
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•

Poor manufacturing
environment
• Poor quality raw materials
• Few manufacturers
• Halt/Delay in
manufacturing
• Foreign drugs not
inspected
• Consolidation of market
• Non-sterility due to
contamination
Sterile Injectable Drug
Problems

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

•
•
•
•

Commonly in shortage
Few manufacturers
High burden on hospitals
Frequently used in
anesthesia delivery
Manufacturers/Single Source
•
•
•
•

Generic market has few
manufacturers
Prescription Drug WrapUp Program
Single subcontractor
supplies multiple
manufacturers
Supply disruptions
quickly lead to shortage
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Regulatory Factors: Federal
•

Prescription Drug WrapUp Program
• Unintentional
hyperinflation
• Drug Enforcement
Agency decreasing
allocated product quotas
of narcotics in response to
opioid epidemic
• Prices are reflective of
market forces
• No price controls
Lack of Transparency in
Shortages

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

•

Poor transparency in
manufacturing disruption
• Hospitals may lack
resources to timely
information
• Limited transparency into
foreign manufacturers
• Reasons for shortages not
frequently disclosed
• Duration of expected
shortage not specific
Economic Factors for
Manufacturers and Health
Care Centers
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•

Prescription Drug WrapUp Program
• Sole source medications
• Inflexible hospital
reimbursements
• Single supplier for a given
disease
• Low profit margins
• Just in time inventory
practices leads to
hospitals have limited
stockpile of excess drug
Hospital & Patient Costs
1 = not
• Higher costs for hospitals relevant
& patients
• Higher cost of alternatives
• Increased labor costs
• Longer hospitalization
• Drug price inflation
outpacing hospital
reimbursement
Natural Disasters
•

•

Consolidation of
manufacturing into one
geographic area increases
risk during a natural
disaster
Destruction of raw
materials

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment
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•

Disrupted transportation
of drugs
National Security Concerns

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

•

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

•

1 = not
relevant

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

Reliance on foreign
countries for active
pharmaceutical
ingredients
• Foreign manufacturer
inspection is not robust
• United States military and
Veterans Administration
hospitals vulnerable to
shortages
• Trade susceptible to
political unrest
• Quality control impacts
active pharmaceutical
ingredients
Ethical Considerations
Patients are poorly
informed
• Patients prefer to be
informed
• Delays/Cancellations to
care
Policy and Procedure
Development
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•

Develop hospital-based
drug supply management
policy
• Establish criteria for use
of drug in shortage
• Change par levels in
automated dispensing
cabinets
• Monitor drug availability
• Daily assessment of
inventory
• Protocol development for
substitution of enteral
opioids for intravenous
administration
• Policy development for
delay/cancelling elective
surgeries
Pharmacy Based Interventions
•
•
•
•

Change par levels in
automated dispensing
cabinets
Ration drugs
Purchase more expensive
product/alternative
concentrations
Compound shortage drugs
in-house

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant
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4 = highly
relevant

Comment

Quality Improvement Hospitals
•

Work with electronic
health record vendor to
quickly change drug
concentration/brand
• Divide larger vials into
single-dose syringes
Best Practices Anesthesia
Providers Drug Shortages
•
•

•

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

1 = not
relevant

2 = somewhat
relevant

3 = quite
relevant

4 = highly
relevant

Comment

Educate anesthesia staff
on new practice
changes/alternatives
Develop departmental
strategy to communicate
problems with Pharmacy
and Pharmacy and
Therapeutics Committee
Avoid waste
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Appendix C
IRB Exemption Letter

Human Subjects Research Determination

January 25, 2022

Type of Review: Initial
Project Title: An Evidence based teaching plan for novice certified registered
nurse anesthetists on medication shortage safety threats and management
Investigator: Robert Simon
IRB ID: IRB-2022-860
Dear Robert Simon,
The planned activity noted above was reviewed by a member of the EHN IRB
and determined not to be human subjects research. This decision only applies to
the planned activity described in the materials provided to the IRB. As the person
accountable for the conduct of the activity, you are responsible for ensuring that it
is conducted as described in the materials provided.
Before this project can be initiated, you must email Derrick Crump, the Chief
Privacy Officer, the following to confirm all HIPAA regulations will be followed:
•
•
•
•
•
•
•

The activity description
The plan for data use
The plan for data protection (limited access, when and how data is stored,
password protection, etc.)
Any materials submitted within this determination and that will be used to
carry out your planned activity
Any data collection and master/linking sheets
Any surveys/questionnaires
Description of recruitment activities including invitations (if applicable)

If any data that is being collected for this project will be used for student
requirements to earn a degree for an external school or institution (i.e., doing the
study and collecting data for your dissertation, Master's Degree, etc., you must
contact Tahirah Harrigan to confirm that all student requirements have been met
and Derrick Crump, the Chief Privacy Officer, to confirm that a data sharing
agreement is needed and/or signed.
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Please note that any data collected for this activity cannot be analyzed and
presented for another purpose, unless an updated project description and
analysis plan is approved by the IRB. Although much can be learned from these
types of activities and sharing your findings is strongly encouraged, this activity
as currently described cannot be referred to as "human subject research" when
discussed in publications and presentations. Innovative Programs (IP) and
Quality Improvement (QI) projects should not be described or analyzed as a
“study” or “research” in publications or presentations, but should be clearly
identified as a "program", "program evaluation" or “QI project”. An acceptable
statement that could be included in the manuscript would be, "This project was
reviewed and determined not to meet the definition of human subject research by
the EHN IRB."
If you wish to analyze and present the data collected for your project/program as
part of a human subject research study, please call the IRB Office at 215-4567217 to discuss whether a new application must be submitted to the IRB for
review prior to initiating this activity.

Sincerely,
Beth Lynch, CIP
Senior IRB Analyst
This message is intended for the use of the person or entity to which it is
addressed and may contain information that is privileged and confidential, the
disclosure of which is governed by applicable law. If you are not the intended
recipient, or the employee or agent responsible to deliver it to the intended
recipient, you are hereby notified that any disclosure, copying, or distribution of
this information is strictly prohibited. If you have received this message by error,
please notify the sender immediately to arrange for return or destruction of these
documents.
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Appendix D
La Salle IRB Letter

18 February 2022

TO:

Patricia Dillon, PhD, RN
Chair of Graduate, RN to BSN and RN to MSN Nursing Programs

FROM:

Susan C. Borkowski, Ph.D.
Chair, Institutional Review Board

RE:

Post BSN - DNP Anesthesia Students' Projects

The La Salle University Institutional Review Board [IRB] accepts Einstein Hospital’s
IRB assessment of the Post BSN - DNP Anesthesia Students' Projects as non-human
research.
These projects focus on quality improvement and do not involve human subjects. Based
on the Einstein determination, La Salle’s IRB does not require the submission of a formal
IRB proposal.
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